Welcome to Needham

Needham & Company, LLC, a subsidiary of The Needham Group, Inc., is a nationally recognized investment banking and asset management firm focused solely on growth companies and their investors. Needham’s mission is to provide its clients with the long-term advice they need to achieve their business goals. The Firm's commitment to exceptional service is unusual in today’s business climate, and is born of a tradition which stresses integrity above all else. We strive to be front of mind, approachable and idea driven. Needham is actively engaged in the public and private capital markets, boasting a 32-year track record of executing complex transactions and the accompanying reputation for excellence in our markets.

Needham’s principal activities involve assisting our clients through a variety of advisory and transaction-related services, with a specific focus on:

 

To check the background of our Firm on FINRA’s BrokerCheck , click here



  • Athersys, Inc. (NASDAQ:ATHX) is an international biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the neurological, cardiovascular and inflammatory and immune disease areas, and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research institutions to further develop its platform and products.

    Athersys, Inc. raised $23.0 million in its follow-on offering at $1.01 per share. Needham acted as lead manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 2,970,300 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Athersys, Inc. for working capital and general corporate purposes, including funding towards its Phase 3 MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study-2 ("MASTERS-2") clinical study and its other ongoing clinical programs.

  • Applied Micro Circuits Corporation (NASDAQ: AMCC) is a global leader in computing andconnectivity solutions for next-generation cloud infrastructure and data centers. AppliedMicro delivers silicon solutions that dramatically lower total cost of ownership. Corporate headquarters are located in Sunnyvale, California. AppliedMicro became a wholly owned subsidiary of MACOM on 01/26/2017.

    Applied Micro Circuits Corporation (NASDAQ: AMCC), a global leader in computing and connectivity solutions, completed its previously announced sale to MACOM Technology Solutions Holdings, Inc. (NASDAQ: MTSI), a leading supplier of high-performance RF, microwave, millimeterwave, and lightwave semiconductor products, for $764.9 million in the form of an exchange offer. Needham & Company acted as exclusive financial advisor to Applied Micro Circuits.

  • Kornit Digital (NASDAQ: KRNT) develops, manufactures and markets industrial digital printing technologies for the garment, apparel and textile industries. Kornit delivers complete solutions, including digital printing systems, inks, consumables, software and after-sales support. Leading the digital direct-to-garment printing market with its exclusive eco-friendly NeoPigment printing process, Kornit caters directly to the changing needs of the textile printing value chain. Kornit’s technology enables innovative business models based on web-to-print, on-demand and mass customization concepts. With its immense experience in the direct-to-garment market, Kornit also offers a revolutionary approach to the roll-to-roll textile printing industry: digitally printing with a single ink set onto multiple types of fabric with no additional finishing processes. Founded in 2003, Kornit Digital is a global company, headquartered in Israel with offices in the USA, Europe and Asia Pacific, and serves customers in more than 100 countries worldwide.

    Kornit Digital, Ltd. raised $142.3 million in its upsized follow-on offering public offering. Of the 7,500,000 ordinary shares, 2,000,000 of the shares are being offered by Kornit and 5,500,000 of the shares are being offered by shareholders of the company, substantially all by the company’s largest shareholder, Fortissimo Capital Fund II (Israel) LP at $16.50 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,125,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Kornit Digital for general corporate purposes. The Company will not receive any of the proceeds from the sale of shares being offered by the selling shareholders.

  • Exablox is the company reimagining storage. Exablox solves businesses’ runaway storage costs and information management nightmares by providing a cloud-managed, scale-out, object-based solution that is affordable and easy to use. OneBlox is an inclusive storage offering that combines an elegant hardware architecture and integrated, enterprise-grade software, including inline deduplication, continuous data protection and disaster recovery. Exablox’s innovative approach to storage has led to widespread customer traction across verticals including higher education, healthcare, insurance and the legal as well as Fortune 500 companies. As of January 19, 2017, Exablox Corporation operates as a subsidiary of StorageCraft Technology Corporation.

    Exablox Corporation, the award-winning company reimagining storage, completed its sale to StorageCraft, the intelligent recovery and backup company. StorageCraft Technology Corporation and Exablox Corporation joined forces to completely focus on helping businesses analyze, protect, and store their data. The new entity is the first company to bring together a new approach that recognizes the disappearing lines between primary and secondary storage as well as between data availability and data protection. The terms of the transaction have not been publicly disclosed. Needham & Company acted as exclusive financial advisor to Exablox Corporation.

  • Mediafly is an enterprise software company that has worked with some of the most respected global sales organizations. The Mediafly Evolved Selling Platform™ aligns with every sales training methodology and is a proven technology for helping field sales organizations deliver a dynamic, interactive, insightful buying experience that ties seamlessly back to CRM. For the third year in a row, Mediafly has been recognized by Inc. Magazine as one of the top 5000 fastest-growing private companies in the US. For more information, visit www.mediafly.com.

    Mediafly, a leading enterprise software company designed to help companies transform and evolve how they sell through the delivery of a perfect in-person selling experience, announced the closing of a $10 million growth capital investment from Boathouse Capital. This is the first outside institutional round for the company and will provide Mediafly with a financial partner to support industry leading product innovation to meet the growing demand for more effective sales tools from organizations around the world. As part of the transaction, Andy Jang, Vice President at Boathouse Capital, will be joining Mediafly's Board of Directors. Needham & Company acted as exclusive financial advisor to Mediafly on this transaction.

  • Ichor Holdings, Ltd. (NASDAQ: ICHR) is a leader in the design, engineering and manufacturing of critical fluid delivery subsystems for semiconductor capital equipment. Our primary offerings include gas and chemical delivery subsystems, collectively known as fluid delivery subsystems, which are key elements of the process tools used in the manufacturing of semiconductor devices. Our gas delivery subsystems deliver, monitor and control precise quantities of the specialized gases used in semiconductor manufacturing processes such as etch and deposition. Our chemical delivery subsystems precisely blend and dispense the reactive liquid chemistries used in semiconductor manufacturing processes such as electroplating and cleaning. We also manufacture certain components for internal use in fluid delivery systems and for direct sales to our customers. This vertically integrated portion of our business is primarily focused on metal and plastic parts that are used in gas and chemical systems, respectively.

    Ichor Holdings, Ltd. raised $60.84 million in its initial public offering at $9.00 per share. Needham acted as a passive bookrunner on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 881,667 shares of common stock at the initial public offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Ichor Holdings to repay outstanding borrowings under their Credit Facilities and the remainder for general corporate purposes, including funding working capital, operating expenses and the selective pursuit of business development opportunities in their focus segment areas.

  • Impinj (NASDAQ:PI) is a leading provider of RAIN RFID solutions. The Impinj Platform connects billions of everyday items such as apparel, medical supplies, automobile parts, drivers’ licenses, food and luggage to applications such as inventory management, patient safety, asset tracking and item authentication, delivering real-time information to businesses about items they create, manage, transport and sell. The Impinj Platform wirelessly delivers information about these items’ unique identity, location and authenticity, or Item Intelligence™, to the digital world, which Impinj believes is the essence of the Internet of Things.

    Impinj, Inc. raised $109.2 million in its follow-on offering at $27.00 per share. Needham acted as lead manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 527,380 shares of common stock at the follow-on offering price to cover over-allotments. The number of shares sold in the offering included 1,527,380 shares sold by Impinj and 2,515,869 shares sold by certain selling stockholders. The net proceeds from the sale of the shares from the offering will be used by Impinj, Inc. for general corporate purposes, which may include working capital, capital expenditures, other corporate expenses, and acquisitions of complementary products, technologies or businesses. Impinj did not receive any proceeds from the sale of the shares by the selling stockholders.

  • TTM Technologies, Inc. (NASDAQ: TTMI) is a major global printed circuit board manufacturer, focusing on quick-turn and technologically advanced PCBs, backplane assemblies and electro-mechanical solutions. TTM stands for time-to-market, representing how TTM's time-critical, one-stop manufacturing services enable customers to shorten the time required to develop new products and bring them to market.

    TTM Technologies, Inc. raised $158.7 million in its follow-on offering of 12,000,000 shares of its common stock by its largest stockholder, Su Sih (BVI) Ltd. (the “Selling Stockholder”) at $11.50 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,800,000 shares of common stock at the follow-on offering price to cover over-allotments from the Selling Stockholder. The Selling Stockholder will receive all of the proceeds from the offering.

  • MSP Corporation is an instrumentation and equipment company creating products for scientific research and industrial applications. They are known worldwide for their expertise in micro- and nano-particles and their creative use in research and manufacturing. MSP is the world leader in cascade impactor technology with products serving the pharmaceutical and aerosol research markets, as well nano-particle generation and measurement technology serving the semiconductor device fabrication market. The company offers products through its distribution network worldwide. MSP Corporation was incorporated in 1985 and is based in Shoreview, Minnesota. As of November 9, 2016, MSP Corporation operates as a subsidiary of TSI Incorporated.

    MSP Group, an instrumentation and equipment company with an expertise in micro- and nano-particles and their creative use in research and manufacturing, completed its sale to TSI Incorporated, an industry leader in the design and production of precision instruments for measurements relating to aerosol science, air flow, health and safety, indoor air quality, fluid dynamics and biohazard detection. The terms of the transaction have not been publicly disclosed. Needham & Company acted as exclusive financial advisor to MSP Group.

  • The Chinese consortium of investors was comprised of Beijing-based IC design and solutions manufacturer Chipone Technology Co., Ltd ("Chipone") and its financial partner Beijing E-Town International Investment & Development Co., Ltd. ("E-Town Capital"). It focuses on technology, media and telecommunications, clean technology, semiconductors, and modern information service industry.

    A Chinese consortium comprised of Beijing-based IC design and solutions manufacturer Chipone Technology Co., Ltd ("Chipone") and its financial partner Beijing E-Town International Investment & Development Co., Ltd. ("E-Town Capital") announced that it has completed the acquisition of the Integrated Memory Logic Limited (iML) subsidiary of Exar Corporation (NYSE: EXAR), a leading supplier of analog mixed-signal semiconductor components and system solutions serving the industrial, high-end consumer and infrastructure markets, for a net purchase price of $136.0 million in cash. Needham & Company acted as exclusive financial advisor to the Chinese consortium.

  • Lavante, Inc. designs and develops a cloud-based supplier information management (SIM) and profit recovery system for Fortune 1000 companies. The company offers Lavante SIM, a transformational tool to manage and validate supplier profile automatically; Lavante Recovery, an on-demand recovery auditing solution; and Lavante Connect, a platform for connecting companies and suppliers. It serves hospitality, retail, entertainment, manufacturing, and medical industries. The company was formerly known as AuditSolutions Inc. and changed its name to Lavante, Inc. in April 2009. Lavante, Inc. was founded in 2001 and is based in San Jose, California. As of October 31, 2016, Lavante, Inc. operates as a subsidiary of PRGX USA, Inc.

    Lavante, Inc., a SaaS-based procure-to-pay (P2P) supplier information management (SIM) and recovery audit services firm, completed its sale to PRGX Global, Inc. (Nasdaq: PRGX), a global leader in Recovery Audit and Spend Analytics services. The terms of the transaction have not been publicly disclosed. Needham & Company acted as exclusive financial advisor to Lavante, Inc.

  • Theravance Biopharma, Inc. (NASDAQ: TBPH) is a diversified biopharmaceutical company with the core purpose of creating medicines that help improve the lives of patients suffering from serious illness. Our pipeline of internally discovered product candidates includes potential best-in-class medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. VIBATIV® (telavancin), our first commercial product, is a once-daily dual-mechanism antibiotic approved in the U.S., Europe and certain other countries for certain difficult-to-treat infections. Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a potential once-daily, nebulized treatment for chronic obstructive pulmonary disease (COPD). Our neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of major cardiovascular and renal diseases, including acute and chronic heart failure, hypertension and chronic kidney diseases, such as diabetic nephropathy. Our research efforts are focused in the areas of inflammation and immunology, with the goal of designing medicines that provide targeted drug delivery to tissues in the lung and gastrointestinal tract in order to maximize patient benefit and minimize risk. The first program to emerge from this research is designed to develop intestinally restricted pan-Janus kinase (JAK) inhibitors for the treatment of a range of inflammatory intestinal diseases. In addition, we have an economic interest in future payments that may be made by Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain drug development programs, including the Closed Triple (the combination of fluticasone furoate, umeclidinium, and vilanterol), currently in development for the treatment of COPD and asthma. For more information, please visit www.theravance.com.

    Theravance Biopharma, Inc. raised $115.1 million in its follow-on offering at $26.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 577,500 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Theravance Biopharma, Inc. for general corporate purposes, which may include, among other things, research activities, preclinical and clinical development of product candidates, manufacture of pre-clinical, clinical and commercial drug supplies, selling and marketing expenses, capital expenditures, working capital, general and administrative expenses and acquisitions of technology or drug candidates.

  • Theravance Biopharma, Inc. (NASDAQ: TBPH) is a diversified biopharmaceutical company with the core purpose of creating medicines that help improve the lives of patients suffering from serious illness. Our pipeline of internally discovered product candidates includes potential best-in-class medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. VIBATIV® (telavancin), our first commercial product, is a once-daily dual-mechanism antibiotic approved in the U.S., Europe and certain other countries for certain difficult-to-treat infections. Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a potential once-daily, nebulized treatment for chronic obstructive pulmonary disease (COPD). Our neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of major cardiovascular and renal diseases, including acute and chronic heart failure, hypertension and chronic kidney diseases, such as diabetic nephropathy. Our research efforts are focused in the areas of inflammation and immunology, with the goal of designing medicines that provide targeted drug delivery to tissues in the lung and gastrointestinal tract in order to maximize patient benefit and minimize risk. The first program to emerge from this research is designed to develop intestinally restricted pan-Janus kinase (JAK) inhibitors for the treatment of a range of inflammatory intestinal diseases. In addition, we have an economic interest in future payments that may be made by Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain drug development programs, including the Closed Triple (the combination of fluticasone furoate, umeclidinium, and vilanterol), currently in development for the treatment of COPD and asthma. For more information, please visit www.theravance.com.

    Theravance Biopharma, Inc. issued $230.0 million principal amount of Convertible Senior Notes due 2023. The Notes will be general unsecured obligations of the Company and will pay interest semi-annually on May 1 and November 1 of each year at a rate of 3.25% per year. The initial conversion rate of the Notes is 29.0276 ordinary shares per $1,000 principal amount of the Notes (which is equivalent to an initial conversion price of approximately $34.45 per share), and will be subject to adjustment upon the occurrence of certain events. The initial conversion price represents a conversion premium of approximately 32.5% over the sale price of ordinary shares sold in the Shares Offering. The Notes will mature on November 1, 2023, unless earlier repurchased or converted. The Notes will be convertible into ordinary shares of the Company at the then-applicable conversion rate until the close of business on the second business day immediately preceding the stated maturity date. The Notes will not be redeemable at the Company's option prior to maturity except in connection with certain changes in tax laws. Holders of the Notes will have the right to require the Company to repurchase all or any portion of their notes at 100% of their principal amount, plus any accrued and unpaid interest, upon the occurrence of certain fundamental change events. The underwriters fully exercised their option to purchase an additional $30 million in aggregate principal amount of debentures to cover overallotments. Needham & Company acted as a co-manager for this transaction. The Company intends to use the net proceeds of the offerings for general corporate purposes, which may include, among other things, research activities, preclinical and clinical development of product candidates, manufacture of pre-clinical, clinical and commercial drug supplies, selling and marketing expenses, capital expenditures, working capital, general and administrative expenses and acquisitions of technology or drug candidates.

  • Quantenna Communications, Inc. (NASDAQ: QNTA) is a provider of high-performance Wi-Fi solutions. Quantenna’s solutions combine semiconductor architecture with system-level software and cloud analytics with the goal of delivering the highest speed, broadest coverage, highest capacity, and most reliable performance. Quantenna’s solutions primarily serve the non-mobile device market.

    Quantenna Communications, Inc. raised $108.4 million in its initial public offering at $16.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters exercised their option to purchase an additional 75,466 shares of common stock at the initial public offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Quantenna Communications for general corporate purposes, including working capital, operating expenses and capital expenditures. The company may also use a portion of the net proceeds to acquire complementary businesses, products, services or technologies.

  • Collegium Pharmaceutical, Inc. (Nasdaq:COLL) is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx technology platform for the treatment of chronic pain. The DETERx oral drug delivery technology is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.

    Collegium Pharmaceutical, Inc. raised $92.0 million in its follow-on offering at $16.00 per share. Needham acted as a co-lead manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 750,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Collegium Pharmaceutical, Inc. for the continued commercialization of Xtampza; funding research and development efforts of its other product candidates; and working capital and general corporate purposes, which may include the acquisition or licensing of product candidates, technologies, compounds, other assets or complementary businesses.

  • Everspin Technologies (NASDAQ: MRAM) is the leading provider of MRAM solutions. Everspin’s MRAM solutions offer the persistence of non-volatile memory with the speed and endurance of random access memory (RAM), and enable the protection of mission critical data particularly in the event of power interruption or failure. Everspin’s MRAM solutions allow its customers in the industrial, automotive and transportation, and enterprise storage markets to design high performance, power efficient and reliable systems without the need for bulky batteries or capacitors. Everspin is the only provider of commercially available MRAM solutions and over the past eight years has shipped over 60 million MRAM units. For more information, visit www.everspin.com.

    Everspin Technologies raised $40.0 million in its initial public offering at $8.00 per share. Needham acted as a joint-bookrunner on the transaction. The net proceeds from the sale of the shares will be used by Everspin Technologies for are to obtain additional capital, to create a public market for our common stock and to facilitate future access to the public equity markets. The company expects to use the net proceeds received from this offering for working capital and other general corporate purposes, including an estimated payment of $8.5 million due to GLOBALFOUNDRIES in December 2016, research and development activities, sales and marketing activities and capital expenditures, to enhance existing and develop new products, expand our manufacturing capabilities and to fund growth.

  • Acacia Communications (NASDAQ: ACIA) develops, manufactures and sells high-speed coherent optical interconnect products that are designed to transform communications networks through improvements in performance, capacity and cost. By converting optical interconnect technology to a silicon-based technology, a process Acacia refers to as the “siliconization of optical interconnect,” Acacia is able to offer products that meet the needs of cloud and service provider customers in a simple, open, high-performance form factor that can be easily integrated in a cost-effective manner with existing network equipment.

    Acacia Communications, Inc. raised $450.0 million in its follow-on offering at $100.00 per share. The offering consists of 1,210,302 shares from Acacia Communications and 3,289,698 shares from certain existing stockholders. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Acacia Communications, Inc. for working capital and general corporate purposes. Acacia Communications will not receive any of the proceeds from any sale of shares by the selling stockholders.

  • Nutanix, Inc. (NASDAQ: NTNX) makes infrastructure invisible, elevating IT to focus on the applications and services that power their business. The Nutanix enterprise cloud platform leverages web-scale engineering and consumer-grade design to natively converge compute, virtualization and storage into a resilient, software-defined solution with rich machine intelligence. The result is predictable performance, cloud-like infrastructure consumption, robust security, and seamless application mobility for a broad range of enterprise applications.

    Nutanix, Inc. raised $273.61 million in its upsized initial public offering of Class A common stock at $16.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 2,230,500 shares of common stock at the initial public offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Nutanix, Inc. for general corporate purposes, including working capital, sales and marketing activities, research and development and general and administrative matters.

  • Sarepta Therapeutics (NASDAQ: SRPT) is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying DMD drug candidates, including EXONDYS 51, designed to skip exon 51 and approved under the accelerated approval pathway.

    Sarepta Therapeutics, Inc. raised $345.0 million in its follow-on offering at $59.75 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 753,138 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Sarepta Therapeutics, Inc. principally for the continuation and initiation of further clinical trials, commercialization, manufacturing, business development activities including the potential licensing or acquisition of complementary products and technologies and other general corporate purposes.

  • Oclaro, Inc. (NASDAQ: OCLR) is a leader in optical components, modules and subsystems for the core optical, enterprise and data center markets. Leveraging more than three decades of laser technology innovation, photonics integration, and subsystem design, Oclaro's solutions are at the heart of the fast optical networks and high-speed interconnects driving the next wave of streaming video, cloud computing, voice over IP and other bandwidth-intensive and high-speed applications.

    Oclaro, Inc. raised $144.04 million in its upsized follow-on offering at $8.35 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 2,250,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Oclaro, Inc. for general corporate purposes, including working capital, capital expenditures, other corporate expenses and acquisitions of complementary products, technologies or businesses.

  • The Trade Desk, Inc. (NASDAQ: TTD) is a technology company that empowers buyers of advertising. Through its self-service, cloud-based platform, ad buyers can create, manage, and optimize more expressive data-driven digital advertising campaigns across ad formats, including display, video, audio, native and, social, on a multitude of devices, such as computers, mobile devices, and connected TV. Integrations with major data, inventory, and publisher partners ensure maximum reach and decisioning capabilities, and enterprise APIs enable custom development on top of the platform. Headquartered in Ventura, CA, The Trade Desk has offices across the United States, Europe, and Asia.

    The Trade Desk, Inc. raised $96.6 million in its initial public offering of its Class A common stock at $18.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 700,000 shares of common stock at the initial public offering price to cover over-allotments. The Trade Desk will not receive any proceeds from the sale of shares by the selling stockholders.

  • Aquinox Pharmaceuticals, Inc. ("Aquinox") (NASDAQ:AQXP) is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Aquinox's lead drug candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. With a successful Phase 2 clinical trial completed in 2015, Aquinox initiated a Phase 3 trial in 2016 (LEADERSHIP 301) with AQX-1125 for treatment of IC/BPS. Aquinox has a broad intellectual property portfolio and pipeline of preclinical drug candidates that activate SHIP1.

    Aquinox Pharmaceuticals, Inc. raised $75.4 million in its follow-on offering at $12.25 per share. Needham acted as a lead manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 802,500 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Aquinox Pharmaceuticals, Inc. to fund additional clinical development of AQX-1125 and to fund pre-commercial and market assessment activities, research and development costs to advance its pipeline of preclinical product candidates and for working capital and other general corporate purposes.

  • DFMSim provides advanced enabling software solutions to the global semiconductor industry. The company's technology simulates key IC design and processing steps to quickly find and avoid systemic defects that threaten yields and increase manufacturing costs. DFMSim's solutions are versatile, modular, easy to use and can be rapidly configured for various manufacturing processes and tools. Headquartered in Silicon Valley, the company maintains R&D, sales and support offices in multiple global locations.

    DFMSim Inc., a leader in chip simulation technology, completed its sale to Applied Materials (NASDAQ: AMAT), the global leader in providing innovative equipment, services and software to enable the manufacture of advanced semiconductor, flat panel display and solar photovoltaic products. The terms of the transaction have not been publicly disclosed. Needham & Company acted as the exclusive financial advisor to DFMSim Inc.

  • Inphi Corporation (NYSE: IPHI) is a leader in high-speed data movement. We move big data - fast, throughout the globe, between data centers, and inside data centers. Inphi's expertise in signal integrity results in reliable data delivery, at high speeds, over a variety of distances. As data volumes ramp exponentially due to video streaming, social media, cloud-based services, and wireless infrastructure, the need for speed has never been greater. That's where we come in. Customers rely on Inphi's solutions to develop and build out the Service Provider and Cloud infrastructures, and data centers of tomorrow.

    Inphi Corporation issued $287.5 million principal amount of Convertible Senior Notes due 2021 in an upsized transaction to qualified institutional buyers pursuant to an exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). Inphi will settle conversions of the notes by paying or delivering, as the case may be, cash, shares of its common stock, or a combination of cash and shares of its common stock, at its election. In addition, holders may require Inphi to repurchase their notes upon the occurrence of a fundamental change (as defined in the indenture governing the notes) at a purchase price equal to the principal amount thereof plus accrued and unpaid interest to, but excluding, the repurchase date. The underwriters fully exercised their option to purchase an additional $37.5 million in aggregate principal amount of notes to cover over-allotments. Needham & Company acted as a co-manager for this transaction. Inphi intends to use a portion of the net proceeds from the offering of the notes to pay the cost of certain capped call transactions. Inphi intends to use the remainder of the net proceeds from the offering of the notes for general corporate purposes, including financing potential acquisitions and other strategic transactions.

  • EMC Corporation (NYSE:EMC) is a global leader in enabling businesses and service providers to transform their operations and deliver IT as a service. Fundamental to this transformation is cloud computing. Through innovative products and services, EMC accelerates the journey to cloud computing, helping IT departments to store, manage, protect and analyze their most valuable asset – information – in a more agile, trusted and cost-efficient way.

    EMC Corporation (NYSE: EMC), a global leader in enabling businesses and service providers to transform their operations and deliver IT as a service, completed its historic previously announced sale to Dell Technologies, creating a unique family of businesses that provides the essential infrastructure for organizations to build their digital future, transform IT and protect their most important asset, information. This combination creates a $74 billion market leader with an expansive technology portfolio that solves complex problems for customers in the industry’s fast-growing areas of hybrid cloud, software-defined data center, converged infrastructure, platform-as-a-service, data analytics, mobility and cybersecurity. Under the terms of the transaction, EMC shareholders received $24.05 per share in cash in addition to tracking stock linked to a portion of EMC’s economic interest in the VMware business. Based on the estimated number of EMC shares outstanding at close, EMC shareholders received 0.11146 shares of new tracking stock (NYSE: DVMT) for each EMC share. It is the largest technology transaction on record and Dell Technologies now becomes the world’s largest privately-controlled technology company. Needham & Company acted as a financial advisor to EMC on this transaction.

  • Galvanize is a dynamic tech learning community that offers education, workspace and networking for students, startups and large companies. Galvanize teaches web development, data science and data engineering to students, offers support and workspace to over 700 member companies and provides over 200 networking events across nine urban campuses throughout the nation. Galvanize campuses bring together entrepreneurs, students, investors, mentors, and great people and companies to develop the skills, mindset and networks necessary to thrive in a technology driven world.

    Galvanize, Inc., a market leader delivering technology education programs and community workspaces, announced a $45 million Series B investment led by ABS Capital Partners, a leading late-stage growth company investor. Colorado Impact Fund, Haystack Partners, Greg Maffei, Aspen Grove Capital and existing investor University Ventures also participated. Needham acted as financial advisor and sole agent to Galvanize on this transaction. The funding will be used to provide more students access to Galvanize’s modern web development and data science programs and directly address employer’s needs to re-skill existing employees. As a result of the financing, Paul Mariani, a general partner with ABS Capital, will join the Galvanize Board of Directors.

  • ACADIA Pharmaceuticals, Inc (NASDAQ: ACAD) is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders.

    ACADIA Pharmaceuticals, Inc. raised $230.0 million in its follow-on offering at $33.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 909,090 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by ACADIA Pharmaceuticals, Inc. for to fund commercialization efforts for NUPLAZID, ongoing and new clinical trials and development efforts for pimavanserin, and for general corporate purposes, which may include research, development and commercialization expenses, capital expenditures, working capital, and sales, general and administrative expenses. The company may also use a portion of the net proceeds to acquire or invest in complementary businesses, products and technologies.

  • Digimarc Corporation (NASDAQ: DMRC), based in Beaverton, Oregon, is the inventor of the Digimarc Discover® platform featuring the imperceptible Digimarc Barcode for automatically identifying and interacting with virtually any media. Digimarc owns an extensive intellectual property portfolio, with patents in digital watermarking, content identification and management, media object discovery, and intuitive computing more generally.

    Digimarc, Inc. raised $42.5 million in its upsized follow-on offering at $30.00 per share. Needham acted as the joint bookrunner on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 185,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Digimarc, Inc. for for general working capital purposes as well as to accelerate the Company’s growth initiatives. These growth initiatives include increasing sales, marketing and operations resources for global expansion; supporting a growing supplier network, and feasibility and pilot projects with prospective customers; continuing development of tools and processes to support efficient, effective and timely implementation of its technology; and further research and intellectual property development.

  • UnboundID provides the industry’s leading software platform for customer identity and access management. Enterprise customers select the UnboundID Platform to modernize traditional Identity and Access Management systems, and enable new customer-facing digital business initiatives that provide real-time personalization and delivery of a consistent customer experience across channels and devices. Some of the world’s largest and most demanding companies in financial services, retail, hospitality, telecommunications and healthcare rely on UnboundID to manage and protect their identity and preference data across application portfolios and systems of engagement. UnboundID customers consistently report a total cost of ownership savings between 25 to 90 percent relative to legacy directory servers, and the company enjoys a 100% customer renewal rate.

    UnboundID, a market leading provider of customer identity and access management software, to help enterprises improve customer engagement, completed its sale to Ping Identity, the leader in Identity Defined Security. Terms of the transaction were not disclosed. The deal puts Ping Identity, which is owned by Vista Equity Partners, firmly in at the intersection of identity and customer engagement and management. The combined company provides Identity and Access Management solutions for the world’s leading companies, including over half of the Fortune 100, and manages over 3 billion identities. Needham & Company acted as the exclusive financial advisor to UnboundID.

  • Ellie Mae, Inc. (NYSE:ELLI) is a leading provider of innovative on-demand software solutions and services for the residential mortgage industry. Mortgage lenders of all sizes use Ellie Mae’s Encompass® all-in-one mortgage management solution, Mavent Compliance Service, and AllRegs research, reference and education resources to improve compliance, loan quality and efficiency across the entire mortgage lifecycle.

    Ellie Mae, Inc. raised $284.63 million in its follow-on offering at $90.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 412,500 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Ellie Mae, Inc. for general corporate purposes, which may include working capital, capital expenditures, other corporate expenses, and acquisitions of complementary products, technologies or businesses.

  • Argos Therapeutics (NASDAQ: ARGS) is an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis® technology platform. Argos' most advanced product candidate, AGS-003, is being evaluated in the pivotal ADAPT Phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). In addition, AGS-003 is being studied in Phase 2 investigator-initiated clinical trials as neoadjuvant therapy for renal cell carcinoma (RCC) and for the treatment of non-small cell lung cancer (NSCLC). Argos is also developing a separate Arcelis®-based product candidate, AGS-004, for the treatment of human immunodeficiency virus (HIV), which is currently being evaluated in an investigator-initiated Phase 2 clinical trial aimed at HIV eradication in adult patients.

    Argos Therapeutics, Inc. raised $50.0 million in its follow-on offering at $5.50 per share of common stock and accompanying warrants . Needham acted as the lead manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Argos Therapeutics, Inc. to fund their pivotal Phase 3 ADAPT trial of AGS-003, the ongoing and planned investigator-initiated Phase 2 clinical trials of AGS-003, their share of the expected costs of the leasing, build-out and equipping of a commercial manufacturing facility and activities in preparation for the submission of a BLA to the FDA for AGS-003, and for working capital and other general corporate purposes.

  • Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an international ophthalmic R&D company, aiming to build a diversified portfolio of therapeutic products addressing the needs of eyecare practitioners and patients around the world.

    Nicox S.A. completed the pricing of an offering a reserved capital increase of ordinary shares of the Company to a specific category of investors. The gross proceeds of the financing are approximately €18 million, for a total of 2,064,000 million new shares. Needham acted as lead placement agent for this transaction. The net proceeds from the sale of the Units will be used by Nicox S.A. for clinical development of pipeline candidates (NCX 4251 in blepharitis and NCX 470 in glaucoma), working capital and general corporate purposes.

  • Impinj (NASDAQ: PI) is a leading provider of RAIN RFID solutions. The Impinj Platform connects billions of everyday items such as apparel, medical supplies, automobile parts, drivers’ licenses, food and luggage to applications such as inventory management, patient safety, asset tracking and item authentication, delivering real-time information to businesses about items they create, manage, transport and sell. The Impinj Platform wirelessly delivers information about these items’ unique identity, location and authenticity, or Item Intelligence™, to the digital world, which Impinj believes is the essence of the Internet of Things.

    Impinj, Inc. raised $77.3 million in its upsized initial public offering at $14.00 per share. Needham acted as a lead manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 720,000 shares of common stock at the initial public offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Impinj, Inc. to repay $5.0 million of indebtedness under the mezzanine credit facility and the remainder will be used for working capital and other general corporate purposes.

  • FormFactor, Inc. (NASDAQ: FORM) helps semiconductor manufacturers test the integrated circuits (ICs) that power consumer mobile devices, as well as computing, automotive and other applications. The company is one of the world’s leading providers of essential wafer test technologies and expertise, with an extensive portfolio of high-performance probe cards for DRAM, Flash and SoC devices. Customers use FormFactor’s products and services to lower overall production costs, improve their yields and enable complex next-generation ICs. Headquartered in Livermore, California, the company services its customers from a network of facilities in Europe, Asia and North America.

    FormFactor, Inc. (Nasdaq:FORM) announced that it has completed the acquisition of Cascade Microtech, Inc. (NASDAQ: CSCD),a worldwide leader in precision contact, electrical measurement and test of integrated circuits (ICs), optical devices and other small structures, for a net purchase price of $352 million in cash and stock. Needham & Company acted as the exclusive financial advisor and provided a fairness opinion to the Board of Directors of FormFactor, Inc. as part of its services.

  • Selecta Biosciences, Inc. (NASDAQ: SELB) is a clinical-stage biopharmaceutical company developing targeted therapies that use immunomodulators encapsulated in nanoparticles to induce antigen-specific immune responses to prevent and treat disease. Selecta's proprietary Synthetic Vaccine Particle (SVP) technology is a highly flexible nanoparticle platform, capable of incorporating a wide range of antigens and immunomodulators, allowing the SVP products to either induce antigen-specific tolerance or activate the immune system. Selecta's focus is on developing and commercializing differentiated therapies that are designed to modulate the immune system to effectively and safely treat rare diseases by mitigating the formation of anti-drug antibodies (ADAs) in response to life-sustaining biologic drugs. Tolerance-inducing SVP products also have potential applications in the treatment of allergies and autoimmune diseases. Selecta is also developing SVP products that activate the immune system to prevent and treat cancer, infections and other diseases. Selecta is based in Watertown, Massachusetts, USA.

    Selecta Biosciences, Inc. raised $74.1 million in its upsized initial public offering at $14.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters exercised their option to purchase an additional 289,633 shares of common stock at the initial public offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Selecta Biosciences to support the clinical development of SEL-212, conduct preclinical studies in order to advance the development of Selecta’s other SVP product candidates and for working capital and general corporate purposes.

  • SCYNEXIS, Inc. (NASDAQ: SCYX) is a pharmaceutical company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. SCYNEXIS is developing its lead product candidate, SCY-078, as an oral and IV drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections.

    SCYNEXIS, Inc. raised $22.5 million in its follow-on offering of 9,375,000 shares of its common stock and warrants to purchase 4,218,750 shares of its common stock. The shares and warrants are being sold at a public offering price of $2.40 per share. The shares of common stock and warrants will be issued separately. The warrants are exercisable immediately upon issuance, have a five-year term and an exercise price of $3.00 per share. Needham acted as the co-lead manager on the transaction. The net proceeds from the sale of the shares and warrants from the offering will be used by SCYNEXIS, Inc. for general corporate purposes, which may include working capital, capital expenditures, other corporate expenses, and strategic acquisitions.

  • Medgenics, Inc. (NYSE: MDGN) is dedicated to unlocking the potential of genomic medicine to identify and treat patients with life-altering conditions. Its efforts, including its internal research and development and ongoing sponsored research and licensing agreements with a well-respected pediatric academic medical center, give Medgenics the ability to focus on the underlying genetic pathway of pediatric diseases with the goal of finding therapeutic solutions for subpopulations of both children and adults living with rare and other difficult-to-treat diseases. Medgenics is also the developer of TARGT™ (Transduced Autologous Restorative Gene Therapy), a proprietary gene therapy platform.

    Medgenics, Inc. raised $21.1 million in its follow-on offering at $5.50 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters exercised their option to purchase an additional 196,363 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Medgenics, Inc. to fund (i) product development activities, including the development of companion diagnostics for existing programs, (ii) patent maintenance fees and intellectual property support, (iii) licensing and research collaborations and (iv) general corporate purposes and working capital, which may include the acquisitions or licensing of complementary technologies, products or businesses.

  • GigPeak, Inc. (NYSE MKT:GIG) is a leading innovator of semiconductor ICs and software solutions for high-speed connectivity and high-quality video compression over the Network and the Cloud. The focus of the company is to develop and deliver products that enable lower power consumption and faster data connectivity, more efficient use of network infrastructure, broader connectivity to the Cloud, and reduce the total cost of ownership of existing network pipes from the core to the end user. GigPeak addresses both the speed of data transmission and the amount of bandwidth the data consumes within the network, and provides solutions that increase the efficiency of the Internet of Things, leveraging its strength in high-speed connectivity and high quality video compression. The extended product portfolio provides more flexibility to support changing market requirements from ICs and MMICs through full software programmability and cost efficient custom ASICs.

    GigPeak, Inc. raised $28.8 million in its follow-on offering at $2.00 per share. Needham acted as a joint bookrunner on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,875,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by GigPeak, Inc. for potential acquisitions for strategic growth, including to acquire critical technologies and scalable businesses. It intends to focus on multiple global attractive acquisition targets.

  • Dermira, Inc. (NASDAQ:DERM) is a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases. Dermira’s portfolio includes three late-stage product candidates that target significant unmet needs and market opportunities: CIMZIA® (certolizumab pegol), in Phase 3 development in collaboration with UCB Pharma S.A. for the treatment of moderate-to-severe chronic plaque psoriasis; DRM04, in Phase 3 development for the treatment of primary axillary hyperhidrosis (excessive underarm sweating); and DRM01, in Phase 2b development for the treatment of facial acne vulgaris. Dermira is headquartered in Menlo Park, California.

    Dermira, Inc. raised $144.9 million in its follow-on offering at $28.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 675,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Dermira, Inc. will enable the Company to complete and generate topline results from their ongoing Phase 3 clinical trials for Cimzia and their planned Phase 3 clinical trials for DRM01; complete the ARIDO trial and other registration-enabling activities and submit an NDA to the FDA for potential approval related to DRM04; enable UCB to submit a supplemental Biologics License Application to the FDA for potential approval of Cimzia; and commercialize at least one of their product candidates assuming that the Company receives the necessary regulatory approvals.

  • Clearside Biomedical, Inc. (NASDAQ: CLSD), is a late-stage clinical biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye using Clearside’s proprietary suprachoroidal space (SCS™) microinjector to reach diseased tissue through the suprachoroidal space. Clearside holds intellectual property protecting the delivery of drugs of any type through the suprachoroidal space to reach the back of the eye.

    Clearside Biomedical, Inc. raised $50.4 million in its initial public offering at $7.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters exercised their option to purchase an additional 948,843 shares of common stock at the initial public offering price to cover over-allotments.The net proceeds from the sale of the shares will be used by Clearside Biomedical, Inc. for funding of the Company’s pivotal Phase 3 clinical trial of CLS-1001, its Phase 2 clinical trial of CLS-1003 and its preparation of an IND for, and subsequent Phase 1/2 clinical trial of, CLS-1002. The remaining proceeds will be used for the continued research and development of earlier-stage programs, and for working capital and general corporate purposes.

  • RADCOM (NASDAQ: RDCM) is a first-mover and leading provider of NFV-ready service assurance and customer experience management solutions for Communications Service Providers (CSPs). RADCOM's software - MaveriQ - continuously monitors network performance and quality of services, to optimize user experience for CSPs' subscribers. RADCOM specializes in solutions for next-generation mobile and fixed networks, including LTE, VoLTE, IMS and others. MaveriQ enables CSPs to smoothly migrate their networks to NFV by assuring physical, NFV-based and hybrid networks.

    RADCOM Ltd. raised $23.0 million in its follow-on offering at $11.00 per share. Needham acted as the lead manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 272,727 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by RADCOM for general corporate purposes, which may include financing its operations, capital expenditures and business development.

  • Acacia Communications (NASDAQ: ACIA) develops, manufactures and sells high-speed coherent optical interconnect products that are designed to transform communications networks through improvements in performance, capacity and cost. By converting optical interconnect technology to a silicon-based technology, a process Acacia refers to as the "siliconization of optical interconnect," Acacia is able to offer products that meet the needs of cloud and service provider customers in a simple, open, high-performance form factor that can be easily integrated in a cost-effective manner with existing network equipment.

    Acacia Communications, Inc. raised $119.03 million in its initial public offering at $23.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 675,000 shares of common stock at the initial public offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Acacia Communications for for working capital and general corporate purposes. Acacia Communications will not receive any of the proceeds from any sale of shares by the selling stockholders.

  • Solair is an Italian provider of an innovative IoT software platform to customers across a number of industries, including manufacturing, retail, food & beverage and transportation.

    Solair, an Italian provider of an innovative IoT software platform to customers across a number of industries, including manufacturing, retail, food & beverage and transportation, completed its previously announced sale to Microsoft Corporation (NASDAQ: MSFT), a multinational technology company that develops, manufactures, licenses, supports and sells computer software, consumer electronics and personal computers and services. The terms of the transaction have not been publicly disclosed. Needham & Company acted as the exclusive financial advisor to Solair.

  • Rocketick Technologies, Ltd. is an Israel-based pioneer and leading provider of multicore parallel simulation. Rocketick’s market-leading technology achieves linear speed-up by parallelizing simulation on standard x86-based multicore servers, providing automated partitioning across designs and testbenches, and the flexibility to direct simulations to server farm resources ranging from one to 64 cores. It also provides a significant accuracy advantage and enhanced visibility with four-state logic simulation, and reduces host memory footprint by 2-3X for gate-level designs.

    Rocketick Technologies, Ltd., an Israel-based pioneer and leading provider of multicore parallel simulation, completed its previously announced sale to Cadence Design Systems, Inc. (NASDAQ: CDNS), a technology company that enables global electronic design innovation and plays an essential role in the creation of today's integrated circuits and electronics. The terms of the transaction have not been publicly disclosed. Needham & Company acted as the exclusive financial advisor to Rocketick Technologies, Ltd..

  • Aeglea (NASDAQ: AGLE) is a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. The company’s engineered human enzymes are designed to degrade specific amino acids in the blood in order to reduce toxic levels of amino acids in inborn errors of metabolism or to exploit the dependence of certain cancers on specific amino acids. In addition to the ongoing Phase 1 clinical trial in oncology with its lead product candidate AEB1102, Aeglea expects to begin trials in 2016 of AEB1102 in patients with Arginase I deficiency. The company is building a pipeline of additional product candidates targeting key amino acids, including AEB4104, which degrades homocystine, a target for an inborn error of metabolism, as well as two potential treatments for cancer, AEB3103, which degrades cysteine/cystine, and AEB2109, which degrades methionine.

    Aeglea BioTherapeutics, Inc. raised $54.82 million in its upsized initial public offering at $10.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters exercised their option to purchase an additional 481,940 shares of common stock at the initial public offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Aeglea BioTherapeutics, Inc. for general corporate purposes including working capital, product development and operating expenses.

  • Celator Pharmaceuticals, Inc. (NASDAQ: CPXX), with locations in Ewing, N.J., and Vancouver, B.C., is an oncology-focused biopharmaceutical company that is transforming the science of combination therapy, and developing products to improve patient outcomes in cancer. Celator's proprietary technology platform, CombiPlex®, enables the rational design and rapid evaluation of optimized combinations of anti-cancer drugs, incorporating traditional chemotherapies as well as molecularly targeted agents to deliver enhanced anti-cancer activity. CombiPlex addresses several fundamental shortcomings of conventional combination regimens, as well as the challenges inherent in combination drug development, by identifying the most effective synergistic molar ratio of the drugs being combined in vitro, and fixing this ratio in a nano-scale drug delivery complex to maintain the optimized combination after administration and ensuring exposure of this ratio to the tumor. Celator's lead product is VYXEOS™ (also known as CPX-351), a nano-scale liposomal formulation of cytarabine:daunorubicin in Phase 3 clinical testing for the treatment of acute myeloid leukemia. We have also conducted clinical development on CPX-1, a nano-scale liposomal formulation of irinotecan:floxuridine studied in colorectal cancer; and have a preclinical stage product candidate, CPX-8, a hydrophobic docetaxel prodrug nanoparticle formulation. More recently, the Company has advanced its CombiPlex platform and broadened its application to include molecularly targeted therapies.

    Celator Pharmaceuticals, Inc. raised $43.7 million in its follow-on offering at $9.50 per share. Needham acted as lead manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 600,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Celator Pharmaceuticals, Inc. to fund initial launch activities, commercialization of VYXEOS, advance the pipeline of clinical stage assets and for general corporate purposes.

  • ANADIGICS, Inc. (NASDAQ: ANAD) designs and manufactures innovative radio frequency (RF) solutions for the growing CATV infrastructure, small-cell, WiFi, and cellular markets. Headquartered in Warren, NJ, ANADIGICS offers RF products with exceptional reliability, performance and integration to deliver a unique competitive advantage to OEMs and ODMs for infrastructure and mobile applications. The Company’s award-winning solutions include line amplifiers, upstream amplifiers, power amplifiers, front-end ICs, front-end modules and other RF components.

    ANADIGICS, Inc. (NASDAQ: ANAD), a world leader in radio frequency (RF) solutions, completed its previously announced sale to II‐VI Incorporated (NASDAQ: IIVI), a leader in engineered materials and optoelectronic components for approximately $78.2 million in cash. Needham & Company acted as the exclusive financial advisor to ANADIGICS, Inc.

  • IntegriChain is the leading channel management cloud used by life sciences suppliers, including nine of the top 10 pharmaceutical manufacturers, to drive channel collaboration and to improve the efficiency of how products reach customers. Pharmaceutical, biopharm/specialty pharma, generics, and consumer health suppliers use IntegriChain to manage their supply chain relationships, inventories, and orders across a vast network of retailers, ecommerce, and distributors. As a suite of informed applications and analytics built on top of aggregated channel inventory and point-of-sale (POS) data, IntegriChain provides customer operations, national accounts, and finance teams with a collaborative, agile, and mobile alternative to ERP and homegrown systems. By embedding big-data customer insights into daily business processes, IntegriChain helps control the high cost of product distribution while improving product availability, ensuring a higher level of revenue predictability and maximizing distribution investment. More than $200 billion in annual U.S. commerce and 2 billion transactions flow through the IntegriChain Cloud annually. IntegriChain is backed by Accel-KKR, a leading technology private equity firm.

    IntegriChain, the leading channel management cloud used by life sciences suppliers has received a strategic equity investment from Accel-KKR, a technology-focused investment firm with $4.0 billion in capital commitments to its current funds. Under the terms of the investment, Accel-KKR will acquire 100% of the equity not held by members of IntegriChain's management team. Needham & Company acted as the exclusive financial advisor to IntegriChain.

  • ThermiGen LLC is a privately held medical aesthetics technology company and a leading developer and manufacturer of thermistor-regulated energy systems for plastic surgery and aesthetics dermatology applications. The Thermi flagship product is the ThermiRF®, Temperature Controlled Radio Frequency Generator System, which is FDA cleared for dermatological and general surgical procedures for electrocoagulation and hemostasis, and to create lesions in nervous tissue. ThermiRF®, is an advanced technology using finely controlled thermal energy. It is a multi-use platform which uses proprietary hand pieces designed for specific medical applications and promotes increased patient safety and clinical effectiveness, while providing versatile solutions for physicians serving the aesthetic market.

    ThermiGen LLC, a privately held medical aesthetics technology company and a leading developer and manufacturer of thermistor-regulated energy systems for plastic surgery and aesthetics dermatology applications, completed its previously announced sale to Almirall, S.A., a global pharmaceutical company based in Barcelona, Spain. In September 2015, Almirall acquired a minority stake in ThermiGen for $5 million representing 7.7% of the share capital of the company and paid $2.5 million in exchange of a call option right to acquire up to 100% of the company for an Enterprise Value of approximately $80 million. The call option to acquire 100% of the share capital of ThermiGen LLC was exercised by Almirall. Needham & Company acted as the exclusive financial advisor to ThermiGen LLC.

  • PMC (NASDAQ: PMCS) is the semiconductor and software solutions innovator transforming networks that connect, move and store big data. Building on a track record of technology leadership, PMC is driving innovation across storage, optical and mobile networks. PMC's highly integrated solutions increase performance and enable next-generation services to accelerate the network transformation.

    PMC-Sierra, Inc., a leading innovator of energy-saving films and glass products for automotive and architectural markets, completed its previously announced sale to Microsemi Corporation (Nasdaq: MSCC) ("Microsemi"), a leading provider of semiconductor solutions differentiated by power, security, reliability and performance. Under the terms of the agreement, PMC-Sierra's shareholders have received $9.22 in cash and 0.0771 of a share of Microsemi common stock for each share of PMC common stock through an exchange offer. Needham & Company acted as a financial advisor to PMC-Sierra, Inc.

  • Collegium Pharmaceutical, Inc. (NASDAQ: COLL) is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx oral drug delivery technology is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.

    Collegium Pharmaceutical, Inc. raised $55.0 million in its follow-on offering at $20.00 per share. Needham acted as co-lead manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Collegium Pharmaceutical, Inc. for general corporate purposes, which may include working capital, capital expenditures, other corporate expenses, and acquisitions of complementary products, technologies or businesses.

  • Akebia Therapeutics, Inc. (NASDAQ: AKBA) is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Akebia has completed Phase 2 development of its lead product candidate, vadadustat (formerly AKB-6548), an oral therapy for the treatment of anemia related to CKD in both non-dialysis and dialysis patients. Enrollment in the PRO2TECT™ Phase 3 program in non-dialysis patients commenced in late 2015 and the INNO2VATE™ Phase 3 program in dialysis-dependent CKD patients is expected to commence in 2016.

    Akebia Therapeutics, Inc. raised $65.3 million in its follow-on offering at $9.00 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Akebia Therapeutics, Inc. offering to fund continued clinical development of vadadustat in patients with anemia secondary to chronic kidney disease (CKD), including to prepare, initiate and conduct its PRO2TECT™ Phase 3 program and to prepare and initiate its planned INNO2VATE™ Phase 3 program, to advance AKB-6899 through Phase 1 development in oncology, and the remainder for working capital and other general corporate purposes.

  • ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. ACADIA has a pipeline of product candidates led by NUPLAZID™ (pimavanserin), for which we have submitted a New Drug Application (NDA) in Parkinson’s disease psychosis to the FDA and which has the potential to be the first drug approved in the United States for this condition. The FDA has classified the NUPLAZID NDA as having Priority Review status. Pimavanserin is also in Phase II development for Alzheimer’s disease psychosis and has successfully completed a Phase II trial in schizophrenia. ACADIA also has clinical-stage programs for glaucoma and, in collaboration with Allergan, Inc., for chronic pain.

    ACADIA Pharmaceuticals Inc. raised $300.0 million in its follow-on offering at $29.00 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by ACADIA Pharmaceuticals Inc. . to fund commercialization efforts for NUPLAZID, ongoing and new clinical trials and development efforts for pimavanserin, and for general corporate purposes, which may include research, development and commercialization expenses, capital expenditures, working capital, and general and administrative expenses. We may also use a portion of the net proceeds to acquire or invest in complementary businesses, products and technologies.

  • Cempra, Inc. (NASDAQ: CEMP) is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates are currently in advanced clinical development. Solithromycin (CEM-101) has successfully completed two Phase 3 clinical trials for community-acquired bacterial pneumonia (CABP) and is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan. Solithromycin is also in a Phase 3 clinical trial for uncomplicated urogenital urethritis caused by Neisseria gonorrhoeae or chlamydia. Cempra is contracted with BARDA for the development of solithromycin for pediatric use. Three formulations, intravenous, oral capsules and a suspension formulation are in a Phase 1b trial in children from birth to 17 years of age. Taksta™ is Cempra's second product candidate, which is being developed for acute bacterial skin and skin structure Infections (ABSSSI) and is also expected to be tested in an exploratory study for chronic oral treatment of refractory infections in bones and joints. Both products seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra has also synthesized novel macrolides for non-antibiotic uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Cempra was founded in 2006 and is headquartered in Chapel Hill, N.C.

    Cempra, Inc. raised $100.0 million in its follow-on offering at $24.00 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Cempra, Inc. to fund the commercial launch of solithromycin in community acquired bacterial pneumonia (CABP) in the U.S., subject to the drug receiving FDA approval for such an indication, research and development activities, including the continued clinical and regulatory development of solithromycin in CABP and gonorrhea and Taksta in acute bacterial skin and skin structure infections (ABSSSI) and also for the chronic oral treatment of refractory infections in bones and joints, as well as for working capital and general corporate and administrative expenses.

  • Yirendai (NYSE: YRD) is a leading online consumer finance marketplace in China connecting investors and individual borrowers. The Company provides an effective solution to address largely underserved investor and individual borrower demand in China through an online platform that automates key aspects of its operations to efficiently match borrowers with investors and execute loan transactions. Yirendai deploys a proprietary risk management system, which enables the Company to effectively assess the creditworthiness of borrowers, appropriately price the risks associated with borrowers, and offer quality loan investment opportunities to investors. Yirendai's online marketplace provides borrowers with quick and convenient access to consumer credit at competitive prices and investors with easy and quick access to an alternative asset class with attractive returns.

    Yirendai Ltd. raised $75 million in its initial public offering at $10.00 per share. Needham acted as a passive bookrunner on the transaction. The net proceeds from the sale of the shares will be used by Yirendai Ltd. for general corporate purposes, which may include investment in product development, sales and marketing activities, technology infrastructure, capital expenditures, improvement of corporate facilities and other general and administrative matters. The company may also use a portion of these proceeds for the acquisition of, or investment in, technologies, solutions or businesses that complement the company’s business.

  • Pertino is a new way to WAN for the mobile and cloud era—secure, software-defined and delivered as a service. Mobile and cloud technologies are transforming IT, resulting in a hybrid IT model where distributed workforces and workloads are reliant on the Internet. Our Cloud Network Engine platform enables enterprises to build and manage private cloud networks that overlay the public Internet, securely connecting people, devices and resources anywhere. With AppScape, our network services app store, Pertino cloud networks can be extended with enterprise-level visibility, security and control services. This modern approach to networking combines the power and pervasiveness of the cloud with SDN and virtualization technologies to eliminate cost and complexity. Finally, a WAN that is cloud-agile and works the way organizations work today, without hardware, hassles, or high costs. Founded in 2011, Pertino is venture funded by premier firms and headquartered in Los Gatos, California.

    Pertino, a privately-held Silicon Valley company that has pioneered the use of software-defined networking to deliver cloud-based networks as-a-service for enterprise and SMB customers worldwide, completed its previously announced sale to Cradlepoint, the global leader in software-defined 4G LTE network solutions for enterprises. The terms of the transaction were not disclosed. Needham & Company acted as the exclusive financial advisor to Pertino.

  • The Chinese consortium of investors was led by SummitView Capital and includes eTown MemTek, Hua Capital, and Huaqing Jiye Investment Management. Summitview Capital is a private equity firm specializing in buyouts. It focuses on technology, media and telecommunications, clean technology, semiconductors, and modern information service industry. Summitview Capital is based in Shanghai China, with an additional office in Changzhou, China.

    A Chinese consortium of investors led by SummitView Capital and that includes eTown MemTek, Hua Capital, and Huaqing Jiye Investment Management announced that it has completed the acquisition of Integrated Silicon Solution, Inc. (NASDAQ: ISSI), a global fabless semiconductor company, for a net purchase price of $782.6 million in cash. Needham & Company acted as a financial advisor to the Chinese consortium.

  • Inphi Corporation (NYSE: IPHI) is a leading provider of high-speed, mixed-signal semiconductor solutions for the communications, computing and data center markets. Inphi’s end-to-end data transport platform delivers high signal integrity at leading-edge data speeds, addressing performance and bandwidth bottlenecks in networks, from fiber to memory. Inphi’s solutions minimize latency in computing environments and enable the rollout of next-generation communications infrastructure. Inphi’s solutions provide a vital interface between analog signals and digital information in high-performance systems, such as telecommunications transport systems, enterprise networking equipment, enterprise and data center servers, and storage platforms.

    Inphi Corporation issued $230.0 million principal amount of Convertible Senior Notes due 2020. The size of the offering was increased to $200.0 from the previously announced $150.0 million aggregate principal amount. Prior to June 1, 2020, the notes will be convertible only under certain circumstances and during certain periods, and thereafter, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date. The initial conversion rate for the notes will be 24.8988 shares per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $40.16 per share, and will be subject to adjustment upon the occurrence of certain events. The initial conversion price represents a conversion premium of approximately 35.0% over the last reported sale price of $29.75 per share of Inphi's common stock on The New York Stock Exchange on December 2, 2015. Inphi will settle conversions of the notes by paying or delivering, as the case may be, cash, shares of its common stock, or a combination of cash and shares of its common stock, at its election. In addition, holders may require Inphi to repurchase their notes upon the occurrence of a fundamental change (as defined in the indenture governing the notes) at a purchase price equal to the principal amount thereof plus accrued and unpaid interest to, but excluding, the repurchase date. The underwriters fully exercised their option to purchase an additional $30 million in aggregate principal amount of debentures to cover overallotments. Needham & Company acted as a co-manager for this transaction.

  • Xoom Corporation (NASDAQ: XOOM) is a leading digital money transfer provider that enables consumers to send money, pay bills and send mobile reloads to family and friends around the world in a secure, fast and cost-effective way, using their mobile phone, tablet or computer. During the 12 months ended March 31, 2015, Xoom’s more than 1.3 million active customers sent approximately $7.0 billion with Xoom.

    Xoom Corporation, a digital money transfer provider, completed its previously announced sale to PayPal, Inc. (NASDAQ: PYPL), a provider of a worldwide online payments system. In accordance with the terms of the acquisition agreement announced on July 1, 2015, PayPal acquired all of the outstanding shares of Xoom for $25 per share in cash. Xoom will operate as a separate service within PayPal. Needham & Company acted as a financial advisor and provided a fairness opinion to the Board of Directors of Xoom Corporation as part of its services.

  • Xtera Communications, Inc. (NASDAQ: XCOM) is a leading provider of high-capacity, cost-effective optical transport solutions, supporting the high growth in global demand for bandwidth. Xtera sells solutions to telecommunications service providers, content service providers, enterprises and government entities worldwide. Xtera’s proprietary Wise RamanTM optical amplification technology leads to capacity and reach performance advantages over competitive products. Xtera’s solutions enable cost-effective capacity to meet customers’ bandwidth requirements of today and to support their increasing bandwidth demand fueled by the development of data centers and related cloud-based services.

    XTERA Communications Inc. raised $25.0 million in its offering at $5.00 per share. Needham acted as the lead bookrunner on the transaction. The net proceeds from the sale of the shares will be used by XTERA Communications Inc. for working capital and other general corporate purposes, including to finance our expected growth, develop new products or fund capital expenditures. The Company may also use a portion of the net proceeds to repay borrowings under its credit facility or term loan, or to expand its existing business through acquisitions of other businesses, products or technologies.

  • Athersys, Inc. (NASDAQ:ATHX) is an international biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the neurological, cardiovascular and inflammatory and immune disease areas, and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research institutions to further develop its platform and products.

    Athersys, Inc. raised $23.0 million in its follow-on offering at $1.01 per share. Needham acted as lead manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 2,970,300 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Athersys, Inc. for working capital and general corporate purposes, including funding towards its Phase 3 MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study-2 ("MASTERS-2") clinical study and its other ongoing clinical programs.

  • Applied Micro Circuits Corporation (NASDAQ: AMCC) is a global leader in computing andconnectivity solutions for next-generation cloud infrastructure and data centers. AppliedMicro delivers silicon solutions that dramatically lower total cost of ownership. Corporate headquarters are located in Sunnyvale, California. AppliedMicro became a wholly owned subsidiary of MACOM on 01/26/2017.

    Applied Micro Circuits Corporation (NASDAQ: AMCC), a global leader in computing and connectivity solutions, completed its previously announced sale to MACOM Technology Solutions Holdings, Inc. (NASDAQ: MTSI), a leading supplier of high-performance RF, microwave, millimeterwave, and lightwave semiconductor products, for $764.9 million in the form of an exchange offer. Needham & Company acted as exclusive financial advisor to Applied Micro Circuits.

  • Kornit Digital (NASDAQ: KRNT) develops, manufactures and markets industrial digital printing technologies for the garment, apparel and textile industries. Kornit delivers complete solutions, including digital printing systems, inks, consumables, software and after-sales support. Leading the digital direct-to-garment printing market with its exclusive eco-friendly NeoPigment printing process, Kornit caters directly to the changing needs of the textile printing value chain. Kornit’s technology enables innovative business models based on web-to-print, on-demand and mass customization concepts. With its immense experience in the direct-to-garment market, Kornit also offers a revolutionary approach to the roll-to-roll textile printing industry: digitally printing with a single ink set onto multiple types of fabric with no additional finishing processes. Founded in 2003, Kornit Digital is a global company, headquartered in Israel with offices in the USA, Europe and Asia Pacific, and serves customers in more than 100 countries worldwide.

    Kornit Digital, Ltd. raised $142.3 million in its upsized follow-on offering public offering. Of the 7,500,000 ordinary shares, 2,000,000 of the shares are being offered by Kornit and 5,500,000 of the shares are being offered by shareholders of the company, substantially all by the company’s largest shareholder, Fortissimo Capital Fund II (Israel) LP at $16.50 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,125,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Kornit Digital for general corporate purposes. The Company will not receive any of the proceeds from the sale of shares being offered by the selling shareholders.

  • Exablox is the company reimagining storage. Exablox solves businesses’ runaway storage costs and information management nightmares by providing a cloud-managed, scale-out, object-based solution that is affordable and easy to use. OneBlox is an inclusive storage offering that combines an elegant hardware architecture and integrated, enterprise-grade software, including inline deduplication, continuous data protection and disaster recovery. Exablox’s innovative approach to storage has led to widespread customer traction across verticals including higher education, healthcare, insurance and the legal as well as Fortune 500 companies. As of January 19, 2017, Exablox Corporation operates as a subsidiary of StorageCraft Technology Corporation.

    Exablox Corporation, the award-winning company reimagining storage, completed its sale to StorageCraft, the intelligent recovery and backup company. StorageCraft Technology Corporation and Exablox Corporation joined forces to completely focus on helping businesses analyze, protect, and store their data. The new entity is the first company to bring together a new approach that recognizes the disappearing lines between primary and secondary storage as well as between data availability and data protection. The terms of the transaction have not been publicly disclosed. Needham & Company acted as exclusive financial advisor to Exablox Corporation.

  • Mediafly is an enterprise software company that has worked with some of the most respected global sales organizations. The Mediafly Evolved Selling Platform™ aligns with every sales training methodology and is a proven technology for helping field sales organizations deliver a dynamic, interactive, insightful buying experience that ties seamlessly back to CRM. For the third year in a row, Mediafly has been recognized by Inc. Magazine as one of the top 5000 fastest-growing private companies in the US. For more information, visit www.mediafly.com.

    Mediafly, a leading enterprise software company designed to help companies transform and evolve how they sell through the delivery of a perfect in-person selling experience, announced the closing of a $10 million growth capital investment from Boathouse Capital. This is the first outside institutional round for the company and will provide Mediafly with a financial partner to support industry leading product innovation to meet the growing demand for more effective sales tools from organizations around the world. As part of the transaction, Andy Jang, Vice President at Boathouse Capital, will be joining Mediafly's Board of Directors. Needham & Company acted as exclusive financial advisor to Mediafly on this transaction.

  • Ichor Holdings, Ltd. (NASDAQ: ICHR) is a leader in the design, engineering and manufacturing of critical fluid delivery subsystems for semiconductor capital equipment. Our primary offerings include gas and chemical delivery subsystems, collectively known as fluid delivery subsystems, which are key elements of the process tools used in the manufacturing of semiconductor devices. Our gas delivery subsystems deliver, monitor and control precise quantities of the specialized gases used in semiconductor manufacturing processes such as etch and deposition. Our chemical delivery subsystems precisely blend and dispense the reactive liquid chemistries used in semiconductor manufacturing processes such as electroplating and cleaning. We also manufacture certain components for internal use in fluid delivery systems and for direct sales to our customers. This vertically integrated portion of our business is primarily focused on metal and plastic parts that are used in gas and chemical systems, respectively.

    Ichor Holdings, Ltd. raised $60.84 million in its initial public offering at $9.00 per share. Needham acted as a passive bookrunner on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 881,667 shares of common stock at the initial public offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Ichor Holdings to repay outstanding borrowings under their Credit Facilities and the remainder for general corporate purposes, including funding working capital, operating expenses and the selective pursuit of business development opportunities in their focus segment areas.

  • Impinj (NASDAQ:PI) is a leading provider of RAIN RFID solutions. The Impinj Platform connects billions of everyday items such as apparel, medical supplies, automobile parts, drivers’ licenses, food and luggage to applications such as inventory management, patient safety, asset tracking and item authentication, delivering real-time information to businesses about items they create, manage, transport and sell. The Impinj Platform wirelessly delivers information about these items’ unique identity, location and authenticity, or Item Intelligence™, to the digital world, which Impinj believes is the essence of the Internet of Things.

    Impinj, Inc. raised $109.2 million in its follow-on offering at $27.00 per share. Needham acted as lead manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 527,380 shares of common stock at the follow-on offering price to cover over-allotments. The number of shares sold in the offering included 1,527,380 shares sold by Impinj and 2,515,869 shares sold by certain selling stockholders. The net proceeds from the sale of the shares from the offering will be used by Impinj, Inc. for general corporate purposes, which may include working capital, capital expenditures, other corporate expenses, and acquisitions of complementary products, technologies or businesses. Impinj did not receive any proceeds from the sale of the shares by the selling stockholders.

  • TTM Technologies, Inc. (NASDAQ: TTMI) is a major global printed circuit board manufacturer, focusing on quick-turn and technologically advanced PCBs, backplane assemblies and electro-mechanical solutions. TTM stands for time-to-market, representing how TTM's time-critical, one-stop manufacturing services enable customers to shorten the time required to develop new products and bring them to market.

    TTM Technologies, Inc. raised $158.7 million in its follow-on offering of 12,000,000 shares of its common stock by its largest stockholder, Su Sih (BVI) Ltd. (the “Selling Stockholder”) at $11.50 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,800,000 shares of common stock at the follow-on offering price to cover over-allotments from the Selling Stockholder. The Selling Stockholder will receive all of the proceeds from the offering.

  • MSP Corporation is an instrumentation and equipment company creating products for scientific research and industrial applications. They are known worldwide for their expertise in micro- and nano-particles and their creative use in research and manufacturing. MSP is the world leader in cascade impactor technology with products serving the pharmaceutical and aerosol research markets, as well nano-particle generation and measurement technology serving the semiconductor device fabrication market. The company offers products through its distribution network worldwide. MSP Corporation was incorporated in 1985 and is based in Shoreview, Minnesota. As of November 9, 2016, MSP Corporation operates as a subsidiary of TSI Incorporated.

    MSP Group, an instrumentation and equipment company with an expertise in micro- and nano-particles and their creative use in research and manufacturing, completed its sale to TSI Incorporated, an industry leader in the design and production of precision instruments for measurements relating to aerosol science, air flow, health and safety, indoor air quality, fluid dynamics and biohazard detection. The terms of the transaction have not been publicly disclosed. Needham & Company acted as exclusive financial advisor to MSP Group.

  • The Chinese consortium of investors was comprised of Beijing-based IC design and solutions manufacturer Chipone Technology Co., Ltd ("Chipone") and its financial partner Beijing E-Town International Investment & Development Co., Ltd. ("E-Town Capital"). It focuses on technology, media and telecommunications, clean technology, semiconductors, and modern information service industry.

    A Chinese consortium comprised of Beijing-based IC design and solutions manufacturer Chipone Technology Co., Ltd ("Chipone") and its financial partner Beijing E-Town International Investment & Development Co., Ltd. ("E-Town Capital") announced that it has completed the acquisition of the Integrated Memory Logic Limited (iML) subsidiary of Exar Corporation (NYSE: EXAR), a leading supplier of analog mixed-signal semiconductor components and system solutions serving the industrial, high-end consumer and infrastructure markets, for a net purchase price of $136.0 million in cash. Needham & Company acted as exclusive financial advisor to the Chinese consortium.

  • Lavante, Inc. designs and develops a cloud-based supplier information management (SIM) and profit recovery system for Fortune 1000 companies. The company offers Lavante SIM, a transformational tool to manage and validate supplier profile automatically; Lavante Recovery, an on-demand recovery auditing solution; and Lavante Connect, a platform for connecting companies and suppliers. It serves hospitality, retail, entertainment, manufacturing, and medical industries. The company was formerly known as AuditSolutions Inc. and changed its name to Lavante, Inc. in April 2009. Lavante, Inc. was founded in 2001 and is based in San Jose, California. As of October 31, 2016, Lavante, Inc. operates as a subsidiary of PRGX USA, Inc.

    Lavante, Inc., a SaaS-based procure-to-pay (P2P) supplier information management (SIM) and recovery audit services firm, completed its sale to PRGX Global, Inc. (Nasdaq: PRGX), a global leader in Recovery Audit and Spend Analytics services. The terms of the transaction have not been publicly disclosed. Needham & Company acted as exclusive financial advisor to Lavante, Inc.

  • Theravance Biopharma, Inc. (NASDAQ: TBPH) is a diversified biopharmaceutical company with the core purpose of creating medicines that help improve the lives of patients suffering from serious illness. Our pipeline of internally discovered product candidates includes potential best-in-class medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. VIBATIV® (telavancin), our first commercial product, is a once-daily dual-mechanism antibiotic approved in the U.S., Europe and certain other countries for certain difficult-to-treat infections. Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a potential once-daily, nebulized treatment for chronic obstructive pulmonary disease (COPD). Our neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of major cardiovascular and renal diseases, including acute and chronic heart failure, hypertension and chronic kidney diseases, such as diabetic nephropathy. Our research efforts are focused in the areas of inflammation and immunology, with the goal of designing medicines that provide targeted drug delivery to tissues in the lung and gastrointestinal tract in order to maximize patient benefit and minimize risk. The first program to emerge from this research is designed to develop intestinally restricted pan-Janus kinase (JAK) inhibitors for the treatment of a range of inflammatory intestinal diseases. In addition, we have an economic interest in future payments that may be made by Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain drug development programs, including the Closed Triple (the combination of fluticasone furoate, umeclidinium, and vilanterol), currently in development for the treatment of COPD and asthma. For more information, please visit www.theravance.com.

    Theravance Biopharma, Inc. raised $115.1 million in its follow-on offering at $26.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 577,500 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Theravance Biopharma, Inc. for general corporate purposes, which may include, among other things, research activities, preclinical and clinical development of product candidates, manufacture of pre-clinical, clinical and commercial drug supplies, selling and marketing expenses, capital expenditures, working capital, general and administrative expenses and acquisitions of technology or drug candidates.

  • Theravance Biopharma, Inc. (NASDAQ: TBPH) is a diversified biopharmaceutical company with the core purpose of creating medicines that help improve the lives of patients suffering from serious illness. Our pipeline of internally discovered product candidates includes potential best-in-class medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. VIBATIV® (telavancin), our first commercial product, is a once-daily dual-mechanism antibiotic approved in the U.S., Europe and certain other countries for certain difficult-to-treat infections. Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a potential once-daily, nebulized treatment for chronic obstructive pulmonary disease (COPD). Our neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of major cardiovascular and renal diseases, including acute and chronic heart failure, hypertension and chronic kidney diseases, such as diabetic nephropathy. Our research efforts are focused in the areas of inflammation and immunology, with the goal of designing medicines that provide targeted drug delivery to tissues in the lung and gastrointestinal tract in order to maximize patient benefit and minimize risk. The first program to emerge from this research is designed to develop intestinally restricted pan-Janus kinase (JAK) inhibitors for the treatment of a range of inflammatory intestinal diseases. In addition, we have an economic interest in future payments that may be made by Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain drug development programs, including the Closed Triple (the combination of fluticasone furoate, umeclidinium, and vilanterol), currently in development for the treatment of COPD and asthma. For more information, please visit www.theravance.com.

    Theravance Biopharma, Inc. issued $230.0 million principal amount of Convertible Senior Notes due 2023. The Notes will be general unsecured obligations of the Company and will pay interest semi-annually on May 1 and November 1 of each year at a rate of 3.25% per year. The initial conversion rate of the Notes is 29.0276 ordinary shares per $1,000 principal amount of the Notes (which is equivalent to an initial conversion price of approximately $34.45 per share), and will be subject to adjustment upon the occurrence of certain events. The initial conversion price represents a conversion premium of approximately 32.5% over the sale price of ordinary shares sold in the Shares Offering. The Notes will mature on November 1, 2023, unless earlier repurchased or converted. The Notes will be convertible into ordinary shares of the Company at the then-applicable conversion rate until the close of business on the second business day immediately preceding the stated maturity date. The Notes will not be redeemable at the Company's option prior to maturity except in connection with certain changes in tax laws. Holders of the Notes will have the right to require the Company to repurchase all or any portion of their notes at 100% of their principal amount, plus any accrued and unpaid interest, upon the occurrence of certain fundamental change events. The underwriters fully exercised their option to purchase an additional $30 million in aggregate principal amount of debentures to cover overallotments. Needham & Company acted as a co-manager for this transaction. The Company intends to use the net proceeds of the offerings for general corporate purposes, which may include, among other things, research activities, preclinical and clinical development of product candidates, manufacture of pre-clinical, clinical and commercial drug supplies, selling and marketing expenses, capital expenditures, working capital, general and administrative expenses and acquisitions of technology or drug candidates.

  • Quantenna Communications, Inc. (NASDAQ: QNTA) is a provider of high-performance Wi-Fi solutions. Quantenna’s solutions combine semiconductor architecture with system-level software and cloud analytics with the goal of delivering the highest speed, broadest coverage, highest capacity, and most reliable performance. Quantenna’s solutions primarily serve the non-mobile device market.

    Quantenna Communications, Inc. raised $108.4 million in its initial public offering at $16.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters exercised their option to purchase an additional 75,466 shares of common stock at the initial public offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Quantenna Communications for general corporate purposes, including working capital, operating expenses and capital expenditures. The company may also use a portion of the net proceeds to acquire complementary businesses, products, services or technologies.

  • Collegium Pharmaceutical, Inc. (Nasdaq:COLL) is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx technology platform for the treatment of chronic pain. The DETERx oral drug delivery technology is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.

    Collegium Pharmaceutical, Inc. raised $92.0 million in its follow-on offering at $16.00 per share. Needham acted as a co-lead manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 750,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Collegium Pharmaceutical, Inc. for the continued commercialization of Xtampza; funding research and development efforts of its other product candidates; and working capital and general corporate purposes, which may include the acquisition or licensing of product candidates, technologies, compounds, other assets or complementary businesses.

  • Everspin Technologies (NASDAQ: MRAM) is the leading provider of MRAM solutions. Everspin’s MRAM solutions offer the persistence of non-volatile memory with the speed and endurance of random access memory (RAM), and enable the protection of mission critical data particularly in the event of power interruption or failure. Everspin’s MRAM solutions allow its customers in the industrial, automotive and transportation, and enterprise storage markets to design high performance, power efficient and reliable systems without the need for bulky batteries or capacitors. Everspin is the only provider of commercially available MRAM solutions and over the past eight years has shipped over 60 million MRAM units. For more information, visit www.everspin.com.

    Everspin Technologies raised $40.0 million in its initial public offering at $8.00 per share. Needham acted as a joint-bookrunner on the transaction. The net proceeds from the sale of the shares will be used by Everspin Technologies for are to obtain additional capital, to create a public market for our common stock and to facilitate future access to the public equity markets. The company expects to use the net proceeds received from this offering for working capital and other general corporate purposes, including an estimated payment of $8.5 million due to GLOBALFOUNDRIES in December 2016, research and development activities, sales and marketing activities and capital expenditures, to enhance existing and develop new products, expand our manufacturing capabilities and to fund growth.

  • Acacia Communications (NASDAQ: ACIA) develops, manufactures and sells high-speed coherent optical interconnect products that are designed to transform communications networks through improvements in performance, capacity and cost. By converting optical interconnect technology to a silicon-based technology, a process Acacia refers to as the “siliconization of optical interconnect,” Acacia is able to offer products that meet the needs of cloud and service provider customers in a simple, open, high-performance form factor that can be easily integrated in a cost-effective manner with existing network equipment.

    Acacia Communications, Inc. raised $450.0 million in its follow-on offering at $100.00 per share. The offering consists of 1,210,302 shares from Acacia Communications and 3,289,698 shares from certain existing stockholders. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Acacia Communications, Inc. for working capital and general corporate purposes. Acacia Communications will not receive any of the proceeds from any sale of shares by the selling stockholders.

  • Nutanix, Inc. (NASDAQ: NTNX) makes infrastructure invisible, elevating IT to focus on the applications and services that power their business. The Nutanix enterprise cloud platform leverages web-scale engineering and consumer-grade design to natively converge compute, virtualization and storage into a resilient, software-defined solution with rich machine intelligence. The result is predictable performance, cloud-like infrastructure consumption, robust security, and seamless application mobility for a broad range of enterprise applications.

    Nutanix, Inc. raised $273.61 million in its upsized initial public offering of Class A common stock at $16.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 2,230,500 shares of common stock at the initial public offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Nutanix, Inc. for general corporate purposes, including working capital, sales and marketing activities, research and development and general and administrative matters.

  • Sarepta Therapeutics (NASDAQ: SRPT) is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying DMD drug candidates, including EXONDYS 51, designed to skip exon 51 and approved under the accelerated approval pathway.

    Sarepta Therapeutics, Inc. raised $345.0 million in its follow-on offering at $59.75 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 753,138 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Sarepta Therapeutics, Inc. principally for the continuation and initiation of further clinical trials, commercialization, manufacturing, business development activities including the potential licensing or acquisition of complementary products and technologies and other general corporate purposes.

  • Oclaro, Inc. (NASDAQ: OCLR) is a leader in optical components, modules and subsystems for the core optical, enterprise and data center markets. Leveraging more than three decades of laser technology innovation, photonics integration, and subsystem design, Oclaro's solutions are at the heart of the fast optical networks and high-speed interconnects driving the next wave of streaming video, cloud computing, voice over IP and other bandwidth-intensive and high-speed applications.

    Oclaro, Inc. raised $144.04 million in its upsized follow-on offering at $8.35 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 2,250,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Oclaro, Inc. for general corporate purposes, including working capital, capital expenditures, other corporate expenses and acquisitions of complementary products, technologies or businesses.

  • The Trade Desk, Inc. (NASDAQ: TTD) is a technology company that empowers buyers of advertising. Through its self-service, cloud-based platform, ad buyers can create, manage, and optimize more expressive data-driven digital advertising campaigns across ad formats, including display, video, audio, native and, social, on a multitude of devices, such as computers, mobile devices, and connected TV. Integrations with major data, inventory, and publisher partners ensure maximum reach and decisioning capabilities, and enterprise APIs enable custom development on top of the platform. Headquartered in Ventura, CA, The Trade Desk has offices across the United States, Europe, and Asia.

    The Trade Desk, Inc. raised $96.6 million in its initial public offering of its Class A common stock at $18.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 700,000 shares of common stock at the initial public offering price to cover over-allotments. The Trade Desk will not receive any proceeds from the sale of shares by the selling stockholders.

  • Aquinox Pharmaceuticals, Inc. ("Aquinox") (NASDAQ:AQXP) is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Aquinox's lead drug candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. With a successful Phase 2 clinical trial completed in 2015, Aquinox initiated a Phase 3 trial in 2016 (LEADERSHIP 301) with AQX-1125 for treatment of IC/BPS. Aquinox has a broad intellectual property portfolio and pipeline of preclinical drug candidates that activate SHIP1.

    Aquinox Pharmaceuticals, Inc. raised $75.4 million in its follow-on offering at $12.25 per share. Needham acted as a lead manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 802,500 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Aquinox Pharmaceuticals, Inc. to fund additional clinical development of AQX-1125 and to fund pre-commercial and market assessment activities, research and development costs to advance its pipeline of preclinical product candidates and for working capital and other general corporate purposes.

  • DFMSim provides advanced enabling software solutions to the global semiconductor industry. The company's technology simulates key IC design and processing steps to quickly find and avoid systemic defects that threaten yields and increase manufacturing costs. DFMSim's solutions are versatile, modular, easy to use and can be rapidly configured for various manufacturing processes and tools. Headquartered in Silicon Valley, the company maintains R&D, sales and support offices in multiple global locations.

    DFMSim Inc., a leader in chip simulation technology, completed its sale to Applied Materials (NASDAQ: AMAT), the global leader in providing innovative equipment, services and software to enable the manufacture of advanced semiconductor, flat panel display and solar photovoltaic products. The terms of the transaction have not been publicly disclosed. Needham & Company acted as the exclusive financial advisor to DFMSim Inc.

  • Inphi Corporation (NYSE: IPHI) is a leader in high-speed data movement. We move big data - fast, throughout the globe, between data centers, and inside data centers. Inphi's expertise in signal integrity results in reliable data delivery, at high speeds, over a variety of distances. As data volumes ramp exponentially due to video streaming, social media, cloud-based services, and wireless infrastructure, the need for speed has never been greater. That's where we come in. Customers rely on Inphi's solutions to develop and build out the Service Provider and Cloud infrastructures, and data centers of tomorrow.

    Inphi Corporation issued $287.5 million principal amount of Convertible Senior Notes due 2021 in an upsized transaction to qualified institutional buyers pursuant to an exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). Inphi will settle conversions of the notes by paying or delivering, as the case may be, cash, shares of its common stock, or a combination of cash and shares of its common stock, at its election. In addition, holders may require Inphi to repurchase their notes upon the occurrence of a fundamental change (as defined in the indenture governing the notes) at a purchase price equal to the principal amount thereof plus accrued and unpaid interest to, but excluding, the repurchase date. The underwriters fully exercised their option to purchase an additional $37.5 million in aggregate principal amount of notes to cover over-allotments. Needham & Company acted as a co-manager for this transaction. Inphi intends to use a portion of the net proceeds from the offering of the notes to pay the cost of certain capped call transactions. Inphi intends to use the remainder of the net proceeds from the offering of the notes for general corporate purposes, including financing potential acquisitions and other strategic transactions.

  • EMC Corporation (NYSE:EMC) is a global leader in enabling businesses and service providers to transform their operations and deliver IT as a service. Fundamental to this transformation is cloud computing. Through innovative products and services, EMC accelerates the journey to cloud computing, helping IT departments to store, manage, protect and analyze their most valuable asset – information – in a more agile, trusted and cost-efficient way.

    EMC Corporation (NYSE: EMC), a global leader in enabling businesses and service providers to transform their operations and deliver IT as a service, completed its historic previously announced sale to Dell Technologies, creating a unique family of businesses that provides the essential infrastructure for organizations to build their digital future, transform IT and protect their most important asset, information. This combination creates a $74 billion market leader with an expansive technology portfolio that solves complex problems for customers in the industry’s fast-growing areas of hybrid cloud, software-defined data center, converged infrastructure, platform-as-a-service, data analytics, mobility and cybersecurity. Under the terms of the transaction, EMC shareholders received $24.05 per share in cash in addition to tracking stock linked to a portion of EMC’s economic interest in the VMware business. Based on the estimated number of EMC shares outstanding at close, EMC shareholders received 0.11146 shares of new tracking stock (NYSE: DVMT) for each EMC share. It is the largest technology transaction on record and Dell Technologies now becomes the world’s largest privately-controlled technology company. Needham & Company acted as a financial advisor to EMC on this transaction.

  • Galvanize is a dynamic tech learning community that offers education, workspace and networking for students, startups and large companies. Galvanize teaches web development, data science and data engineering to students, offers support and workspace to over 700 member companies and provides over 200 networking events across nine urban campuses throughout the nation. Galvanize campuses bring together entrepreneurs, students, investors, mentors, and great people and companies to develop the skills, mindset and networks necessary to thrive in a technology driven world.

    Galvanize, Inc., a market leader delivering technology education programs and community workspaces, announced a $45 million Series B investment led by ABS Capital Partners, a leading late-stage growth company investor. Colorado Impact Fund, Haystack Partners, Greg Maffei, Aspen Grove Capital and existing investor University Ventures also participated. Needham acted as financial advisor and sole agent to Galvanize on this transaction. The funding will be used to provide more students access to Galvanize’s modern web development and data science programs and directly address employer’s needs to re-skill existing employees. As a result of the financing, Paul Mariani, a general partner with ABS Capital, will join the Galvanize Board of Directors.

  • ACADIA Pharmaceuticals, Inc (NASDAQ: ACAD) is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders.

    ACADIA Pharmaceuticals, Inc. raised $230.0 million in its follow-on offering at $33.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 909,090 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by ACADIA Pharmaceuticals, Inc. for to fund commercialization efforts for NUPLAZID, ongoing and new clinical trials and development efforts for pimavanserin, and for general corporate purposes, which may include research, development and commercialization expenses, capital expenditures, working capital, and sales, general and administrative expenses. The company may also use a portion of the net proceeds to acquire or invest in complementary businesses, products and technologies.

  • Digimarc Corporation (NASDAQ: DMRC), based in Beaverton, Oregon, is the inventor of the Digimarc Discover® platform featuring the imperceptible Digimarc Barcode for automatically identifying and interacting with virtually any media. Digimarc owns an extensive intellectual property portfolio, with patents in digital watermarking, content identification and management, media object discovery, and intuitive computing more generally.

    Digimarc, Inc. raised $42.5 million in its upsized follow-on offering at $30.00 per share. Needham acted as the joint bookrunner on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 185,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Digimarc, Inc. for for general working capital purposes as well as to accelerate the Company’s growth initiatives. These growth initiatives include increasing sales, marketing and operations resources for global expansion; supporting a growing supplier network, and feasibility and pilot projects with prospective customers; continuing development of tools and processes to support efficient, effective and timely implementation of its technology; and further research and intellectual property development.

  • UnboundID provides the industry’s leading software platform for customer identity and access management. Enterprise customers select the UnboundID Platform to modernize traditional Identity and Access Management systems, and enable new customer-facing digital business initiatives that provide real-time personalization and delivery of a consistent customer experience across channels and devices. Some of the world’s largest and most demanding companies in financial services, retail, hospitality, telecommunications and healthcare rely on UnboundID to manage and protect their identity and preference data across application portfolios and systems of engagement. UnboundID customers consistently report a total cost of ownership savings between 25 to 90 percent relative to legacy directory servers, and the company enjoys a 100% customer renewal rate.

    UnboundID, a market leading provider of customer identity and access management software, to help enterprises improve customer engagement, completed its sale to Ping Identity, the leader in Identity Defined Security. Terms of the transaction were not disclosed. The deal puts Ping Identity, which is owned by Vista Equity Partners, firmly in at the intersection of identity and customer engagement and management. The combined company provides Identity and Access Management solutions for the world’s leading companies, including over half of the Fortune 100, and manages over 3 billion identities. Needham & Company acted as the exclusive financial advisor to UnboundID.

  • Ellie Mae, Inc. (NYSE:ELLI) is a leading provider of innovative on-demand software solutions and services for the residential mortgage industry. Mortgage lenders of all sizes use Ellie Mae’s Encompass® all-in-one mortgage management solution, Mavent Compliance Service, and AllRegs research, reference and education resources to improve compliance, loan quality and efficiency across the entire mortgage lifecycle.

    Ellie Mae, Inc. raised $284.63 million in its follow-on offering at $90.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 412,500 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Ellie Mae, Inc. for general corporate purposes, which may include working capital, capital expenditures, other corporate expenses, and acquisitions of complementary products, technologies or businesses.

  • Argos Therapeutics (NASDAQ: ARGS) is an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis® technology platform. Argos' most advanced product candidate, AGS-003, is being evaluated in the pivotal ADAPT Phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). In addition, AGS-003 is being studied in Phase 2 investigator-initiated clinical trials as neoadjuvant therapy for renal cell carcinoma (RCC) and for the treatment of non-small cell lung cancer (NSCLC). Argos is also developing a separate Arcelis®-based product candidate, AGS-004, for the treatment of human immunodeficiency virus (HIV), which is currently being evaluated in an investigator-initiated Phase 2 clinical trial aimed at HIV eradication in adult patients.

    Argos Therapeutics, Inc. raised $50.0 million in its follow-on offering at $5.50 per share of common stock and accompanying warrants . Needham acted as the lead manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Argos Therapeutics, Inc. to fund their pivotal Phase 3 ADAPT trial of AGS-003, the ongoing and planned investigator-initiated Phase 2 clinical trials of AGS-003, their share of the expected costs of the leasing, build-out and equipping of a commercial manufacturing facility and activities in preparation for the submission of a BLA to the FDA for AGS-003, and for working capital and other general corporate purposes.

  • Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an international ophthalmic R&D company, aiming to build a diversified portfolio of therapeutic products addressing the needs of eyecare practitioners and patients around the world.

    Nicox S.A. completed the pricing of an offering a reserved capital increase of ordinary shares of the Company to a specific category of investors. The gross proceeds of the financing are approximately €18 million, for a total of 2,064,000 million new shares. Needham acted as lead placement agent for this transaction. The net proceeds from the sale of the Units will be used by Nicox S.A. for clinical development of pipeline candidates (NCX 4251 in blepharitis and NCX 470 in glaucoma), working capital and general corporate purposes.

  • Impinj (NASDAQ: PI) is a leading provider of RAIN RFID solutions. The Impinj Platform connects billions of everyday items such as apparel, medical supplies, automobile parts, drivers’ licenses, food and luggage to applications such as inventory management, patient safety, asset tracking and item authentication, delivering real-time information to businesses about items they create, manage, transport and sell. The Impinj Platform wirelessly delivers information about these items’ unique identity, location and authenticity, or Item Intelligence™, to the digital world, which Impinj believes is the essence of the Internet of Things.

    Impinj, Inc. raised $77.3 million in its upsized initial public offering at $14.00 per share. Needham acted as a lead manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 720,000 shares of common stock at the initial public offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Impinj, Inc. to repay $5.0 million of indebtedness under the mezzanine credit facility and the remainder will be used for working capital and other general corporate purposes.

  • FormFactor, Inc. (NASDAQ: FORM) helps semiconductor manufacturers test the integrated circuits (ICs) that power consumer mobile devices, as well as computing, automotive and other applications. The company is one of the world’s leading providers of essential wafer test technologies and expertise, with an extensive portfolio of high-performance probe cards for DRAM, Flash and SoC devices. Customers use FormFactor’s products and services to lower overall production costs, improve their yields and enable complex next-generation ICs. Headquartered in Livermore, California, the company services its customers from a network of facilities in Europe, Asia and North America.

    FormFactor, Inc. (Nasdaq:FORM) announced that it has completed the acquisition of Cascade Microtech, Inc. (NASDAQ: CSCD),a worldwide leader in precision contact, electrical measurement and test of integrated circuits (ICs), optical devices and other small structures, for a net purchase price of $352 million in cash and stock. Needham & Company acted as the exclusive financial advisor and provided a fairness opinion to the Board of Directors of FormFactor, Inc. as part of its services.

  • Selecta Biosciences, Inc. (NASDAQ: SELB) is a clinical-stage biopharmaceutical company developing targeted therapies that use immunomodulators encapsulated in nanoparticles to induce antigen-specific immune responses to prevent and treat disease. Selecta's proprietary Synthetic Vaccine Particle (SVP) technology is a highly flexible nanoparticle platform, capable of incorporating a wide range of antigens and immunomodulators, allowing the SVP products to either induce antigen-specific tolerance or activate the immune system. Selecta's focus is on developing and commercializing differentiated therapies that are designed to modulate the immune system to effectively and safely treat rare diseases by mitigating the formation of anti-drug antibodies (ADAs) in response to life-sustaining biologic drugs. Tolerance-inducing SVP products also have potential applications in the treatment of allergies and autoimmune diseases. Selecta is also developing SVP products that activate the immune system to prevent and treat cancer, infections and other diseases. Selecta is based in Watertown, Massachusetts, USA.

    Selecta Biosciences, Inc. raised $74.1 million in its upsized initial public offering at $14.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters exercised their option to purchase an additional 289,633 shares of common stock at the initial public offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Selecta Biosciences to support the clinical development of SEL-212, conduct preclinical studies in order to advance the development of Selecta’s other SVP product candidates and for working capital and general corporate purposes.

  • SCYNEXIS, Inc. (NASDAQ: SCYX) is a pharmaceutical company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. SCYNEXIS is developing its lead product candidate, SCY-078, as an oral and IV drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections.

    SCYNEXIS, Inc. raised $22.5 million in its follow-on offering of 9,375,000 shares of its common stock and warrants to purchase 4,218,750 shares of its common stock. The shares and warrants are being sold at a public offering price of $2.40 per share. The shares of common stock and warrants will be issued separately. The warrants are exercisable immediately upon issuance, have a five-year term and an exercise price of $3.00 per share. Needham acted as the co-lead manager on the transaction. The net proceeds from the sale of the shares and warrants from the offering will be used by SCYNEXIS, Inc. for general corporate purposes, which may include working capital, capital expenditures, other corporate expenses, and strategic acquisitions.

  • Medgenics, Inc. (NYSE: MDGN) is dedicated to unlocking the potential of genomic medicine to identify and treat patients with life-altering conditions. Its efforts, including its internal research and development and ongoing sponsored research and licensing agreements with a well-respected pediatric academic medical center, give Medgenics the ability to focus on the underlying genetic pathway of pediatric diseases with the goal of finding therapeutic solutions for subpopulations of both children and adults living with rare and other difficult-to-treat diseases. Medgenics is also the developer of TARGT™ (Transduced Autologous Restorative Gene Therapy), a proprietary gene therapy platform.

    Medgenics, Inc. raised $21.1 million in its follow-on offering at $5.50 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters exercised their option to purchase an additional 196,363 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Medgenics, Inc. to fund (i) product development activities, including the development of companion diagnostics for existing programs, (ii) patent maintenance fees and intellectual property support, (iii) licensing and research collaborations and (iv) general corporate purposes and working capital, which may include the acquisitions or licensing of complementary technologies, products or businesses.

  • GigPeak, Inc. (NYSE MKT:GIG) is a leading innovator of semiconductor ICs and software solutions for high-speed connectivity and high-quality video compression over the Network and the Cloud. The focus of the company is to develop and deliver products that enable lower power consumption and faster data connectivity, more efficient use of network infrastructure, broader connectivity to the Cloud, and reduce the total cost of ownership of existing network pipes from the core to the end user. GigPeak addresses both the speed of data transmission and the amount of bandwidth the data consumes within the network, and provides solutions that increase the efficiency of the Internet of Things, leveraging its strength in high-speed connectivity and high quality video compression. The extended product portfolio provides more flexibility to support changing market requirements from ICs and MMICs through full software programmability and cost efficient custom ASICs.

    GigPeak, Inc. raised $28.8 million in its follow-on offering at $2.00 per share. Needham acted as a joint bookrunner on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,875,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by GigPeak, Inc. for potential acquisitions for strategic growth, including to acquire critical technologies and scalable businesses. It intends to focus on multiple global attractive acquisition targets.

  • Dermira, Inc. (NASDAQ:DERM) is a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases. Dermira’s portfolio includes three late-stage product candidates that target significant unmet needs and market opportunities: CIMZIA® (certolizumab pegol), in Phase 3 development in collaboration with UCB Pharma S.A. for the treatment of moderate-to-severe chronic plaque psoriasis; DRM04, in Phase 3 development for the treatment of primary axillary hyperhidrosis (excessive underarm sweating); and DRM01, in Phase 2b development for the treatment of facial acne vulgaris. Dermira is headquartered in Menlo Park, California.

    Dermira, Inc. raised $144.9 million in its follow-on offering at $28.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 675,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Dermira, Inc. will enable the Company to complete and generate topline results from their ongoing Phase 3 clinical trials for Cimzia and their planned Phase 3 clinical trials for DRM01; complete the ARIDO trial and other registration-enabling activities and submit an NDA to the FDA for potential approval related to DRM04; enable UCB to submit a supplemental Biologics License Application to the FDA for potential approval of Cimzia; and commercialize at least one of their product candidates assuming that the Company receives the necessary regulatory approvals.

  • Clearside Biomedical, Inc. (NASDAQ: CLSD), is a late-stage clinical biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye using Clearside’s proprietary suprachoroidal space (SCS™) microinjector to reach diseased tissue through the suprachoroidal space. Clearside holds intellectual property protecting the delivery of drugs of any type through the suprachoroidal space to reach the back of the eye.

    Clearside Biomedical, Inc. raised $50.4 million in its initial public offering at $7.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters exercised their option to purchase an additional 948,843 shares of common stock at the initial public offering price to cover over-allotments.The net proceeds from the sale of the shares will be used by Clearside Biomedical, Inc. for funding of the Company’s pivotal Phase 3 clinical trial of CLS-1001, its Phase 2 clinical trial of CLS-1003 and its preparation of an IND for, and subsequent Phase 1/2 clinical trial of, CLS-1002. The remaining proceeds will be used for the continued research and development of earlier-stage programs, and for working capital and general corporate purposes.

  • RADCOM (NASDAQ: RDCM) is a first-mover and leading provider of NFV-ready service assurance and customer experience management solutions for Communications Service Providers (CSPs). RADCOM's software - MaveriQ - continuously monitors network performance and quality of services, to optimize user experience for CSPs' subscribers. RADCOM specializes in solutions for next-generation mobile and fixed networks, including LTE, VoLTE, IMS and others. MaveriQ enables CSPs to smoothly migrate their networks to NFV by assuring physical, NFV-based and hybrid networks.

    RADCOM Ltd. raised $23.0 million in its follow-on offering at $11.00 per share. Needham acted as the lead manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 272,727 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by RADCOM for general corporate purposes, which may include financing its operations, capital expenditures and business development.

  • Acacia Communications (NASDAQ: ACIA) develops, manufactures and sells high-speed coherent optical interconnect products that are designed to transform communications networks through improvements in performance, capacity and cost. By converting optical interconnect technology to a silicon-based technology, a process Acacia refers to as the "siliconization of optical interconnect," Acacia is able to offer products that meet the needs of cloud and service provider customers in a simple, open, high-performance form factor that can be easily integrated in a cost-effective manner with existing network equipment.

    Acacia Communications, Inc. raised $119.03 million in its initial public offering at $23.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 675,000 shares of common stock at the initial public offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Acacia Communications for for working capital and general corporate purposes. Acacia Communications will not receive any of the proceeds from any sale of shares by the selling stockholders.

  • Solair is an Italian provider of an innovative IoT software platform to customers across a number of industries, including manufacturing, retail, food & beverage and transportation.

    Solair, an Italian provider of an innovative IoT software platform to customers across a number of industries, including manufacturing, retail, food & beverage and transportation, completed its previously announced sale to Microsoft Corporation (NASDAQ: MSFT), a multinational technology company that develops, manufactures, licenses, supports and sells computer software, consumer electronics and personal computers and services. The terms of the transaction have not been publicly disclosed. Needham & Company acted as the exclusive financial advisor to Solair.

  • Rocketick Technologies, Ltd. is an Israel-based pioneer and leading provider of multicore parallel simulation. Rocketick’s market-leading technology achieves linear speed-up by parallelizing simulation on standard x86-based multicore servers, providing automated partitioning across designs and testbenches, and the flexibility to direct simulations to server farm resources ranging from one to 64 cores. It also provides a significant accuracy advantage and enhanced visibility with four-state logic simulation, and reduces host memory footprint by 2-3X for gate-level designs.

    Rocketick Technologies, Ltd., an Israel-based pioneer and leading provider of multicore parallel simulation, completed its previously announced sale to Cadence Design Systems, Inc. (NASDAQ: CDNS), a technology company that enables global electronic design innovation and plays an essential role in the creation of today's integrated circuits and electronics. The terms of the transaction have not been publicly disclosed. Needham & Company acted as the exclusive financial advisor to Rocketick Technologies, Ltd..

  • Aeglea (NASDAQ: AGLE) is a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. The company’s engineered human enzymes are designed to degrade specific amino acids in the blood in order to reduce toxic levels of amino acids in inborn errors of metabolism or to exploit the dependence of certain cancers on specific amino acids. In addition to the ongoing Phase 1 clinical trial in oncology with its lead product candidate AEB1102, Aeglea expects to begin trials in 2016 of AEB1102 in patients with Arginase I deficiency. The company is building a pipeline of additional product candidates targeting key amino acids, including AEB4104, which degrades homocystine, a target for an inborn error of metabolism, as well as two potential treatments for cancer, AEB3103, which degrades cysteine/cystine, and AEB2109, which degrades methionine.

    Aeglea BioTherapeutics, Inc. raised $54.82 million in its upsized initial public offering at $10.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters exercised their option to purchase an additional 481,940 shares of common stock at the initial public offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Aeglea BioTherapeutics, Inc. for general corporate purposes including working capital, product development and operating expenses.

  • Celator Pharmaceuticals, Inc. (NASDAQ: CPXX), with locations in Ewing, N.J., and Vancouver, B.C., is an oncology-focused biopharmaceutical company that is transforming the science of combination therapy, and developing products to improve patient outcomes in cancer. Celator's proprietary technology platform, CombiPlex®, enables the rational design and rapid evaluation of optimized combinations of anti-cancer drugs, incorporating traditional chemotherapies as well as molecularly targeted agents to deliver enhanced anti-cancer activity. CombiPlex addresses several fundamental shortcomings of conventional combination regimens, as well as the challenges inherent in combination drug development, by identifying the most effective synergistic molar ratio of the drugs being combined in vitro, and fixing this ratio in a nano-scale drug delivery complex to maintain the optimized combination after administration and ensuring exposure of this ratio to the tumor. Celator's lead product is VYXEOS™ (also known as CPX-351), a nano-scale liposomal formulation of cytarabine:daunorubicin in Phase 3 clinical testing for the treatment of acute myeloid leukemia. We have also conducted clinical development on CPX-1, a nano-scale liposomal formulation of irinotecan:floxuridine studied in colorectal cancer; and have a preclinical stage product candidate, CPX-8, a hydrophobic docetaxel prodrug nanoparticle formulation. More recently, the Company has advanced its CombiPlex platform and broadened its application to include molecularly targeted therapies.

    Celator Pharmaceuticals, Inc. raised $43.7 million in its follow-on offering at $9.50 per share. Needham acted as lead manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 600,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Celator Pharmaceuticals, Inc. to fund initial launch activities, commercialization of VYXEOS, advance the pipeline of clinical stage assets and for general corporate purposes.

  • ANADIGICS, Inc. (NASDAQ: ANAD) designs and manufactures innovative radio frequency (RF) solutions for the growing CATV infrastructure, small-cell, WiFi, and cellular markets. Headquartered in Warren, NJ, ANADIGICS offers RF products with exceptional reliability, performance and integration to deliver a unique competitive advantage to OEMs and ODMs for infrastructure and mobile applications. The Company’s award-winning solutions include line amplifiers, upstream amplifiers, power amplifiers, front-end ICs, front-end modules and other RF components.

    ANADIGICS, Inc. (NASDAQ: ANAD), a world leader in radio frequency (RF) solutions, completed its previously announced sale to II‐VI Incorporated (NASDAQ: IIVI), a leader in engineered materials and optoelectronic components for approximately $78.2 million in cash. Needham & Company acted as the exclusive financial advisor to ANADIGICS, Inc.

  • IntegriChain is the leading channel management cloud used by life sciences suppliers, including nine of the top 10 pharmaceutical manufacturers, to drive channel collaboration and to improve the efficiency of how products reach customers. Pharmaceutical, biopharm/specialty pharma, generics, and consumer health suppliers use IntegriChain to manage their supply chain relationships, inventories, and orders across a vast network of retailers, ecommerce, and distributors. As a suite of informed applications and analytics built on top of aggregated channel inventory and point-of-sale (POS) data, IntegriChain provides customer operations, national accounts, and finance teams with a collaborative, agile, and mobile alternative to ERP and homegrown systems. By embedding big-data customer insights into daily business processes, IntegriChain helps control the high cost of product distribution while improving product availability, ensuring a higher level of revenue predictability and maximizing distribution investment. More than $200 billion in annual U.S. commerce and 2 billion transactions flow through the IntegriChain Cloud annually. IntegriChain is backed by Accel-KKR, a leading technology private equity firm.

    IntegriChain, the leading channel management cloud used by life sciences suppliers has received a strategic equity investment from Accel-KKR, a technology-focused investment firm with $4.0 billion in capital commitments to its current funds. Under the terms of the investment, Accel-KKR will acquire 100% of the equity not held by members of IntegriChain's management team. Needham & Company acted as the exclusive financial advisor to IntegriChain.

  • ThermiGen LLC is a privately held medical aesthetics technology company and a leading developer and manufacturer of thermistor-regulated energy systems for plastic surgery and aesthetics dermatology applications. The Thermi flagship product is the ThermiRF®, Temperature Controlled Radio Frequency Generator System, which is FDA cleared for dermatological and general surgical procedures for electrocoagulation and hemostasis, and to create lesions in nervous tissue. ThermiRF®, is an advanced technology using finely controlled thermal energy. It is a multi-use platform which uses proprietary hand pieces designed for specific medical applications and promotes increased patient safety and clinical effectiveness, while providing versatile solutions for physicians serving the aesthetic market.

    ThermiGen LLC, a privately held medical aesthetics technology company and a leading developer and manufacturer of thermistor-regulated energy systems for plastic surgery and aesthetics dermatology applications, completed its previously announced sale to Almirall, S.A., a global pharmaceutical company based in Barcelona, Spain. In September 2015, Almirall acquired a minority stake in ThermiGen for $5 million representing 7.7% of the share capital of the company and paid $2.5 million in exchange of a call option right to acquire up to 100% of the company for an Enterprise Value of approximately $80 million. The call option to acquire 100% of the share capital of ThermiGen LLC was exercised by Almirall. Needham & Company acted as the exclusive financial advisor to ThermiGen LLC.

  • PMC (NASDAQ: PMCS) is the semiconductor and software solutions innovator transforming networks that connect, move and store big data. Building on a track record of technology leadership, PMC is driving innovation across storage, optical and mobile networks. PMC's highly integrated solutions increase performance and enable next-generation services to accelerate the network transformation.

    PMC-Sierra, Inc., a leading innovator of energy-saving films and glass products for automotive and architectural markets, completed its previously announced sale to Microsemi Corporation (Nasdaq: MSCC) ("Microsemi"), a leading provider of semiconductor solutions differentiated by power, security, reliability and performance. Under the terms of the agreement, PMC-Sierra's shareholders have received $9.22 in cash and 0.0771 of a share of Microsemi common stock for each share of PMC common stock through an exchange offer. Needham & Company acted as a financial advisor to PMC-Sierra, Inc.

  • Collegium Pharmaceutical, Inc. (NASDAQ: COLL) is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx oral drug delivery technology is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.

    Collegium Pharmaceutical, Inc. raised $55.0 million in its follow-on offering at $20.00 per share. Needham acted as co-lead manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Collegium Pharmaceutical, Inc. for general corporate purposes, which may include working capital, capital expenditures, other corporate expenses, and acquisitions of complementary products, technologies or businesses.

  • Akebia Therapeutics, Inc. (NASDAQ: AKBA) is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Akebia has completed Phase 2 development of its lead product candidate, vadadustat (formerly AKB-6548), an oral therapy for the treatment of anemia related to CKD in both non-dialysis and dialysis patients. Enrollment in the PRO2TECT™ Phase 3 program in non-dialysis patients commenced in late 2015 and the INNO2VATE™ Phase 3 program in dialysis-dependent CKD patients is expected to commence in 2016.

    Akebia Therapeutics, Inc. raised $65.3 million in its follow-on offering at $9.00 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Akebia Therapeutics, Inc. offering to fund continued clinical development of vadadustat in patients with anemia secondary to chronic kidney disease (CKD), including to prepare, initiate and conduct its PRO2TECT™ Phase 3 program and to prepare and initiate its planned INNO2VATE™ Phase 3 program, to advance AKB-6899 through Phase 1 development in oncology, and the remainder for working capital and other general corporate purposes.

  • ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. ACADIA has a pipeline of product candidates led by NUPLAZID™ (pimavanserin), for which we have submitted a New Drug Application (NDA) in Parkinson’s disease psychosis to the FDA and which has the potential to be the first drug approved in the United States for this condition. The FDA has classified the NUPLAZID NDA as having Priority Review status. Pimavanserin is also in Phase II development for Alzheimer’s disease psychosis and has successfully completed a Phase II trial in schizophrenia. ACADIA also has clinical-stage programs for glaucoma and, in collaboration with Allergan, Inc., for chronic pain.

    ACADIA Pharmaceuticals Inc. raised $300.0 million in its follow-on offering at $29.00 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by ACADIA Pharmaceuticals Inc. . to fund commercialization efforts for NUPLAZID, ongoing and new clinical trials and development efforts for pimavanserin, and for general corporate purposes, which may include research, development and commercialization expenses, capital expenditures, working capital, and general and administrative expenses. We may also use a portion of the net proceeds to acquire or invest in complementary businesses, products and technologies.

  • Cempra, Inc. (NASDAQ: CEMP) is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates are currently in advanced clinical development. Solithromycin (CEM-101) has successfully completed two Phase 3 clinical trials for community-acquired bacterial pneumonia (CABP) and is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan. Solithromycin is also in a Phase 3 clinical trial for uncomplicated urogenital urethritis caused by Neisseria gonorrhoeae or chlamydia. Cempra is contracted with BARDA for the development of solithromycin for pediatric use. Three formulations, intravenous, oral capsules and a suspension formulation are in a Phase 1b trial in children from birth to 17 years of age. Taksta™ is Cempra's second product candidate, which is being developed for acute bacterial skin and skin structure Infections (ABSSSI) and is also expected to be tested in an exploratory study for chronic oral treatment of refractory infections in bones and joints. Both products seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra has also synthesized novel macrolides for non-antibiotic uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Cempra was founded in 2006 and is headquartered in Chapel Hill, N.C.

    Cempra, Inc. raised $100.0 million in its follow-on offering at $24.00 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Cempra, Inc. to fund the commercial launch of solithromycin in community acquired bacterial pneumonia (CABP) in the U.S., subject to the drug receiving FDA approval for such an indication, research and development activities, including the continued clinical and regulatory development of solithromycin in CABP and gonorrhea and Taksta in acute bacterial skin and skin structure infections (ABSSSI) and also for the chronic oral treatment of refractory infections in bones and joints, as well as for working capital and general corporate and administrative expenses.

  • Yirendai (NYSE: YRD) is a leading online consumer finance marketplace in China connecting investors and individual borrowers. The Company provides an effective solution to address largely underserved investor and individual borrower demand in China through an online platform that automates key aspects of its operations to efficiently match borrowers with investors and execute loan transactions. Yirendai deploys a proprietary risk management system, which enables the Company to effectively assess the creditworthiness of borrowers, appropriately price the risks associated with borrowers, and offer quality loan investment opportunities to investors. Yirendai's online marketplace provides borrowers with quick and convenient access to consumer credit at competitive prices and investors with easy and quick access to an alternative asset class with attractive returns.

    Yirendai Ltd. raised $75 million in its initial public offering at $10.00 per share. Needham acted as a passive bookrunner on the transaction. The net proceeds from the sale of the shares will be used by Yirendai Ltd. for general corporate purposes, which may include investment in product development, sales and marketing activities, technology infrastructure, capital expenditures, improvement of corporate facilities and other general and administrative matters. The company may also use a portion of these proceeds for the acquisition of, or investment in, technologies, solutions or businesses that complement the company’s business.

  • Pertino is a new way to WAN for the mobile and cloud era—secure, software-defined and delivered as a service. Mobile and cloud technologies are transforming IT, resulting in a hybrid IT model where distributed workforces and workloads are reliant on the Internet. Our Cloud Network Engine platform enables enterprises to build and manage private cloud networks that overlay the public Internet, securely connecting people, devices and resources anywhere. With AppScape, our network services app store, Pertino cloud networks can be extended with enterprise-level visibility, security and control services. This modern approach to networking combines the power and pervasiveness of the cloud with SDN and virtualization technologies to eliminate cost and complexity. Finally, a WAN that is cloud-agile and works the way organizations work today, without hardware, hassles, or high costs. Founded in 2011, Pertino is venture funded by premier firms and headquartered in Los Gatos, California.

    Pertino, a privately-held Silicon Valley company that has pioneered the use of software-defined networking to deliver cloud-based networks as-a-service for enterprise and SMB customers worldwide, completed its previously announced sale to Cradlepoint, the global leader in software-defined 4G LTE network solutions for enterprises. The terms of the transaction were not disclosed. Needham & Company acted as the exclusive financial advisor to Pertino.

  • The Chinese consortium of investors was led by SummitView Capital and includes eTown MemTek, Hua Capital, and Huaqing Jiye Investment Management. Summitview Capital is a private equity firm specializing in buyouts. It focuses on technology, media and telecommunications, clean technology, semiconductors, and modern information service industry. Summitview Capital is based in Shanghai China, with an additional office in Changzhou, China.

    A Chinese consortium of investors led by SummitView Capital and that includes eTown MemTek, Hua Capital, and Huaqing Jiye Investment Management announced that it has completed the acquisition of Integrated Silicon Solution, Inc. (NASDAQ: ISSI), a global fabless semiconductor company, for a net purchase price of $782.6 million in cash. Needham & Company acted as a financial advisor to the Chinese consortium.

  • Inphi Corporation (NYSE: IPHI) is a leading provider of high-speed, mixed-signal semiconductor solutions for the communications, computing and data center markets. Inphi’s end-to-end data transport platform delivers high signal integrity at leading-edge data speeds, addressing performance and bandwidth bottlenecks in networks, from fiber to memory. Inphi’s solutions minimize latency in computing environments and enable the rollout of next-generation communications infrastructure. Inphi’s solutions provide a vital interface between analog signals and digital information in high-performance systems, such as telecommunications transport systems, enterprise networking equipment, enterprise and data center servers, and storage platforms.

    Inphi Corporation issued $230.0 million principal amount of Convertible Senior Notes due 2020. The size of the offering was increased to $200.0 from the previously announced $150.0 million aggregate principal amount. Prior to June 1, 2020, the notes will be convertible only under certain circumstances and during certain periods, and thereafter, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date. The initial conversion rate for the notes will be 24.8988 shares per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $40.16 per share, and will be subject to adjustment upon the occurrence of certain events. The initial conversion price represents a conversion premium of approximately 35.0% over the last reported sale price of $29.75 per share of Inphi's common stock on The New York Stock Exchange on December 2, 2015. Inphi will settle conversions of the notes by paying or delivering, as the case may be, cash, shares of its common stock, or a combination of cash and shares of its common stock, at its election. In addition, holders may require Inphi to repurchase their notes upon the occurrence of a fundamental change (as defined in the indenture governing the notes) at a purchase price equal to the principal amount thereof plus accrued and unpaid interest to, but excluding, the repurchase date. The underwriters fully exercised their option to purchase an additional $30 million in aggregate principal amount of debentures to cover overallotments. Needham & Company acted as a co-manager for this transaction.

  • Xoom Corporation (NASDAQ: XOOM) is a leading digital money transfer provider that enables consumers to send money, pay bills and send mobile reloads to family and friends around the world in a secure, fast and cost-effective way, using their mobile phone, tablet or computer. During the 12 months ended March 31, 2015, Xoom’s more than 1.3 million active customers sent approximately $7.0 billion with Xoom.

    Xoom Corporation, a digital money transfer provider, completed its previously announced sale to PayPal, Inc. (NASDAQ: PYPL), a provider of a worldwide online payments system. In accordance with the terms of the acquisition agreement announced on July 1, 2015, PayPal acquired all of the outstanding shares of Xoom for $25 per share in cash. Xoom will operate as a separate service within PayPal. Needham & Company acted as a financial advisor and provided a fairness opinion to the Board of Directors of Xoom Corporation as part of its services.

  • Xtera Communications, Inc. (NASDAQ: XCOM) is a leading provider of high-capacity, cost-effective optical transport solutions, supporting the high growth in global demand for bandwidth. Xtera sells solutions to telecommunications service providers, content service providers, enterprises and government entities worldwide. Xtera’s proprietary Wise RamanTM optical amplification technology leads to capacity and reach performance advantages over competitive products. Xtera’s solutions enable cost-effective capacity to meet customers’ bandwidth requirements of today and to support their increasing bandwidth demand fueled by the development of data centers and related cloud-based services.

    XTERA Communications Inc. raised $25.0 million in its offering at $5.00 per share. Needham acted as the lead bookrunner on the transaction. The net proceeds from the sale of the shares will be used by XTERA Communications Inc. for working capital and other general corporate purposes, including to finance our expected growth, develop new products or fund capital expenditures. The Company may also use a portion of the net proceeds to repay borrowings under its credit facility or term loan, or to expand its existing business through acquisitions of other businesses, products or technologies.